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A series of mono- and dithiosemicarbazone ligands were prepared by simple 
Schiff-base condensation reactions between thiosemicarbazides and various 
substituted salicylaldehydes. In addition, a new series of thiosemicarbazone 
compounds, which we have called “trithiosemicarbazones”, have been 
prepared using similar chemical procedures as the mono- and 
dithiosemicarbazone compounds. These compounds were characterised 
using elemental analysis, Fourier Transform-Infrared (FT-IR), and Nuclear 
Magnetic Resonance (1H and 13C{1H}) spectroscopy. New compounds were 
also characterised by Electrospray Ionisation mass spectrometry (ESI-MS). 
 
A new series of neutral Pd(II) and Pt(II) PTA mono-, di- and trinuclear 
thiosemicarbazone complexes have also been synthesised using templated 
reactions between various substituted salicylaldimine thiosemicarbazone 
ligands and metal precursors of the general formula cis-[M(PTA)2Cl2], where 
M = Pd or Pt. Characterisation of these complexes was achieved by common 
analytical and spectroscopic techniques: elemental analysis, ESI-MS, FT-IR, 
and NMR (1H, 13C{1H} and 31P{1H}) spectroscopy. Single crystal X-ray 
diffraction was used to confirm the molecular structure of a mononuclear 
Pd(II) derivative and reveals tridentate coordination of the thiosemicarbazone, 
with sulfur in the thiolate form, to the metal centre. In vitro biological 
evaluation of selected complexes and their free ligands was carried out to 
investigate their potential anticancer (against WHCO1 oesophageal cancer 
cells) and antiparasitic activity (against the T1 strain of T. vaginalis). The 
mononuclear Pd(II) complexes were found to display activity in both 
evaluations. In some instances the complexes tested displayed better activity 
than their parent ligands. The dinuclear and some trinuclear complexes did 
not display sufficient solubility in the testing medium and therefore were not 
evaluated.   
 
As an extension of the afore-mentioned study, a series of cationic arene-
ruthenium(II) mono- and dinuclear thiosemicarbazone complexes were 
prepared from the reaction of [Ru(η6-p-cymene)(µ-Cl)Cl]2 and  
[Ru(η6-C6H5(CH2)3COOH)(µ-Cl)Cl]2 with benzaldehyde thiosemicarbazones. 













composition of these complexes. Single crystal structure determination was 
carried out on a mononuclear derivative and revealed coordination of the  
(η6-p-cymene)ruthenium(II) complex in a pseudo-tetrahedral, piano-stool 
conformation. The anticancer activity of these compounds was investigated 
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1.1. Cancer: A brief overview 
Cancer is described as a disease caused by uncontrolled growth and reproduction of 
abnormal cells.1 The invasion of the adjoining parts of the body by the cancer is 
referred to as metastasis. If the spread of these cells is not prevented, death of the 
individual often occurs. Cancer is caused by many factors such as smoking of 
tobacco, chemical exposure to carcinogens or radiation (external factors), as well as 
inherited mutations, hormones and immune conditions (internal factors).1 Most 
cancers require multiple steps in order to develop and the process may take several 
years to reveal itself. Ageing is another factor that contributes to the development of 
cancer. The occurrence of cancer increases dramatically with age and this may be 
due to a build-up of risks for specific cancers. The risk accumulation, combined with 
ineffective cellular repair mechanisms may result in cancer development.2  
 
After heart disease, cancer is the second major cause of death globally. In 2004,  
13% of the deaths that occurred worldwide were directly related to cancer.2 The most 
common cancers that contribute towards millions of deaths each year include breast, 
liver, colorectal, stomach as well as lung cancer.2 Certain cancers can be prevented 
by eliminating exposure to tobacco and other factors that accelerate the process. 
Some malignancies can be detected before cells become cancerous and can be 
treated by surgery, radiotherapy or chemotherapy.3 Targeted therapy is another 
commonly used treatment. Surgery is implemented when the cancerous growth can 
be surgically removed from the body. This usually occurs in the early stages of the 
disease. Radiotherapy uses radiation to treat cancer. The radiotherapy is targeted at 
the cancerous part of the body4 and it uses high energy particles such as radioactive 
sources to destroy or damage these cells.5 Chemotherapy uses drugs to weaken and 
destroy cancer cells in the body, including cells at the original site of cancer and any 
cancer cells that may have spread to other parts of the body.6 Targeted therapy is a 
term that refers to a medication or drug that targets a specific pathway in the 
development of a tumour by blocking these pathways.7 Chemo- and targeted therapy 
are also non-invasive techniques whereby drugs are administered intravenously or 
orally. Some of these drugs include metal-containing compounds that are quite 
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1.2. Metal-containing compounds as anticancer agents 
Metal–containing compounds have been used therapeutically for many years. One of 
the reasons for their frequent use as potential therapeutic agents is due to their high 
reactivity.8-10 The most influential discovery of a metal-containing therapeutic agent 
was made in 1964 when Rosenberg and co-workers11 discovered the anticancer 
activity of cis-diamminedichloroplatinum(II), commonly referred to as cisplatin (Figure 
1.1). To date, cisplatin is regarded as the most effective as well as most frequently 
used anticancer drug.12 It is understood that this compound interacts with DNA 
causing damaging effects which in turn leads to cell apoptosis (programmed cell 
death). Cisplatin is administered into the patient’s bloodstream where it remains 
neutral, however, once it crosses the cell membrane the chlorido atoms are 
displaced by water, giving rise to a cationic metal species. The complex then 
interacts with nitrogen atoms of two adjacent DNA bases (particularly N7 of purine). 
As a result, the DNA becomes bent and is recognised by High-Mobility Group (HMG) 
proteins. These proteins then bind and therefore prevent the repair of the DNA.13  
 
 




    
 
 
Figure 1.1: Cisplatin, a powerful anticancer drug frequently used today 
 
Since the discovery of cisplatin, many structural analogues have been synthesised 
and their biological properties tested. An example of a second generation platinum 
drug is cis-diamine-1,1-cyclobutane dicarboxylate platinum (carboplatin), which is 
similar in structure to cisplatin as it consists of two cis-amines, but differs in that the 
chloride groups are replaced by a bidentate dicarboxylate (Figure 1.2.i). Its biological 
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Although these agents are still in use today, there are some limitations. These arise 
due to the development of drug resistance in various cancer cells. In addition to this, 
they also exhibit some toxic properties.12 Further research into the development of 
structural analogues is therefore crucial to subdue the effects of drug resistance. 
Oxaliplatin (Figure 1.2.ii), another analogue of cisplatin, was found to be an effective 
treatment for gastric cancer and displayed activity against cisplatin resistant cell-
lines.14 
                        











                   
                   i          ii 
  
Figure 1.2: Second generation Pt drugs i) carboplatin and ii) oxaliplatin 
 
With the exception of carboplatin and oxaliplatin, many mononuclear derivatives fail 
to display improved pharmacological properties in comparison to cisplatin when 
undergoing clinical trials.15 This is mainly attributed to the similarities of the cellular 
mechanisms of these mononuclear analogues. In order to overcome this, the idea of 
designing and synthesising multinuclear derivatives was investigated to perhaps give 
rise to compounds possessing innovative mechanisms. Dinuclear platinum 
complexes possessing two platinum centres linked by a variable amine length chain 
were designed with the intent to form different DNA adducts than the mononuclear 
compounds. Specifically, these dinuclear derivatives would form “long-distance” DNA 
cross-links (intra- or interstrand), which are unavailable to the mononuclear 
derivatives.16 To improve on the binding ability of these compounds, trinuclear 
platinum complexes were investigated. BBR3464 (Figure 1.3) is an example of this 
kind of complex. This compound possesses two Pt(NH3)2Cl units linked by a platinum 
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considerable activity of this compound displaying IC50 (drug concentration that 
reduces the number of living cells by 50%) values at least 20-fold lower than 
cisplatin. Further investigation suggested that this compound possessed a distinct 
cellular mechanism of action, which possibly contributes to its potent activity.17 Since 
this discovery, BBR3464 has undergone Phase II clinical trials but was found to be 
highly toxic and therefore further studies with this compound is not recommended.18 
There is therefore scope to develop other multinuclear containing compounds 








Figure 1.3: BBR3464, a multinuclear platinum complex 
 
In addition to platinum, palladium is another example of a platinum group metal 
(PGM) that displays promise in terms of its cytotoxic abilities. Palladium complexes 
are structurally analogous to platinum complexes and many compounds are known 
to exhibit  greater lability when compared to their platinum analogues.19 Palladium–
containing compounds of the form [Pd(en)(L)Cl]NO3 (where en = ethylenediamine 
and L = pyridine, 4-methylpyridine, 4-hydroxypyridine or 4-aminopyridine), Figure 1.4, 
have exhibited cytotoxic behaviour comparable to cisplatin. These compounds have 
displayed activity against the human leukaemia cell-line, HL-60.20  











      R = H, CH3, OH, NH2 
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Until now, very few PGM compounds have reached advanced clinical trial  
stages.21,22 This limited success may be attributed to a lack of structural diversity in 
many of these complexes. 
  
1.3. Thiosemicarbazones: synthesis and anticancer activity 
Thiosemicarbazones are examples of compounds that exhibit great structural 
diversity as they possess various donor atoms, including nitrogen and sulfur, which 
can coordinate to electron-deficient metals (palladium and platinum) in a variety of 
ways. Thiosemicarbazones are prepared by means of Schiff-base condensation 
reactions between thiosemicarbazides (Figure 1.5.i) and substituted 














+         H2O
i                                                                                     ii  
R1, R2 = aryl, alkyl, H 
 
Figure 1.5: The general preparation of many thiosemicarbazones 
   
 Thiosemicarbazones can be classified into three main groups:  
• monothiosemicarbazones (Figure 1.6.i) 
• dithiosemicarbazones (Figure 1.6.ii) 
• bis(thiosemicarbazones) (Figure 1.6.iii) 
 
Monothiosemicarbazones, as their name suggests, consist of one thiosemicarbazone 
moiety, while bis(thiosemicarbazones) consist of two moieties linked via their imine 
nitrogens to an organic spacer. Dithiosemicarbazones also constitute two 
thiosemicarbazone moieties; however, these are linked to an organic spacer via their 
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Figure 1.6: Three classes of thiosemicarbazones i) monothiosemicarbazones 
ii) dithiosemicarbazones iii) bis(thiosemicarbazones) 
 
Thiosemicarbazones have received considerable attention due to their potential 
pharmacological applications.24,25 Monomeric N-heterocyclic 2-formylpyridine26 
(Figure 1.7.i) and 3-hydroxy-2-formylpyridine27,28 (Figure 1.7.ii) thiosemicarbazones 
exhibit anticancer properties. Previous investigation of these anticancer abilities 
revealed that having the heterocyclic atom adjacent to the thiosemicarbazone side 
chain contributes favourably towards the activity of the compound. A conjugated N-N-
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The biological mechanism of action of most thiosemicarbazones involves the 
inhibition of DNA synthesis by three possible mechanisms:30 
 
• blocking of the enzyme ribonucleotide reductase 
• blocking or retarding base replication by binding to DNA 
• or creating DNA ruptures   
 
The mechanism involving ribonucleotide reductase (RNR) is the most widely 
accepted mechanism. RNR is an enzyme responsible for the conversion of the four 
standard nucleotides i.e., 5’-di (or tri) phosphoadenosine, -cytidine, -guanosine and  
–uridine, to their 2’-deoxyribonucleotide counterparts and therefore provides the 
necessary precursors for DNA synthesis and repair.31 Mammalian RNR (Figure 1.8) 
is made up of two subunits, R1 and R2, which provide unique targets to inhibit the 
enzyme.32 R1 is the binding site for nucleotides and is also the target for certain 
anticancer drugs.33 The second subunit, R2, is a metal binding site that requires a 
tyrosine free radical and non-heme iron for its activity.34  
 
Figure 1.8: Ribbon structure of a mouse R2 subunit within ribonucleotide reductase35 
 
A well known thiosemicarbazone RNR inhibitory agent currently being evaluated in 
various clinical trials is 3-aminopyridine-2-carboxaldehyde thiosemicarbazone or 
triapine (Figure 1.9). It has been reported to inhibit the R2 subunit of RNR through 
alteration of the tyrosine free radical and it is also a strong iron chelator.36a Most 






















Figure 1.9: Structure of Triapine, an inhibitor of ribonucleotide reductase 
 
There are a vast number of thiosemicarbazones that display antitumour activity in 
addition to the above mentioned compound. Metal complexes of thiosemicarbazones 
have been synthesised and have also exhibited antitumoural abilities. In some cases 
these complexes displayed enhanced activity in comparison to their ligand 
counterparts. Studies have shown that some thiosemicarbazone complexes of iron 
and copper have shown greater cell destruction than their corresponding ligands.29  
 
1.4. Modes of coordination occurring within thiosemicarbazone complexes 
There are various ways in which metal centres can coordinate to a free 
thiosemicarbazone ligand. Thiosemicarbazones containing two donor atoms such as 
nitrogen and sulfur, are more commonly considered to be bidentate ligands. 
Coordination usually involves dissociation of the hydrazinic proton, resulting in the 
formation of a five-membered chelate ring (Figure 1.10.i).37 Complexation of the 
ligand can also occur in the thione form depending on the metal involved (Figure 
1.10.ii). Tridentate coordination may also occur, provided a third donor site such as 
























        
 i         ii              iii 
 
Figure 1.10: Possible modes of coordination of thiosemicarbazones i) bidentate (thiolate)  
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In addition to the afore-mentioned, there are various other ways in which coordination 
can occur. For example, complexes containing four-membered chelate rings with 
metals such as ruthenium and osmium with salicylaldehyde and benzaldehyde 
thiosemicarbazones have also been reported.38,39 In these cases coordination occurs 







  M = Ru or Os 
 
Figure 1.11: Unusual mode of coordination observed for thiosemicarbazone  
complexes containing ruthenium and osmium 
 
Bis(thiosemicarbazones) are usually tetradentate ligands as coordination of one 
metal centre may occur in an S-N-N-S manner (Figure 1.12.i). The spatial 
arrangement of the sulfur and nitrogen atoms of a dithiosemicarbazone allows for the 
coordination of more than one metal centre (Figure 1.12.ii).23  
  
                                   i              ii 
 
Figure 1.12:  Possible modes of coordination via i) bis(thiosemicarbazones)  
ii) dithiosemicarbazones 
 
1.5. Anticancer activities of some PGM mono- and bis(thiosemicarbazone) 
complexes 
A number of thiosemicarbazone metal complexes have been synthesised and tested 











































thiosemicarbazone complexes include Cu, Au, Ni, Sn, Pd, Pt and Ru.40 More 
pertinent to our study we will look at some examples of platinum group metals 
including palladium, platinum and ruthenium complexes that have been evaluated for 
their anticancer properties. 
 




Polymeric complexes of the type [{Pd(TSC)}n], where TSC = salicylaldehyde 
thiosemicarbazone (TSC1), 2-hydroxyacetophenone thiosemicarbazone (TSC2) or  
2-hydroxynaphthaldehyde thiosemicarbazone (TSC3), were obtained and reaction 
with two monodentate ligands (L), where L = PPh3 or 4-picoline, affording the 
complexes [Pd(TSC1)(L)] (Figure 1.13.i), [Pd(TSC2)(L)] (Figure 1.13.ii) and 
[Pd(TSC3)(L)] (Figure 1.13.iii). These complexes were screened for their cytotoxicity 
along with cisplatin, BCNU, 5-fluorouracil (5-FU) and hydroxyurea, which are clinical 
drugs. These studies were carried out in two human tumour cell-lines, i.e. 
promyelocytic leukaemia (HL-60) and histiocytic lymphoma (U-937). Studies revealed 
that [Pd(TSC2)(PPh3)] showed the lowest IC50 value and was more cytotoxic than the 











L = PPh3, 4-picoline 
 
Figure 1.13: Palladium complexes of the general form [Pd(TSC)(L)] that exhibit cytotoxicity  
i                                              ii  































Pd(II) complexes of 2-benzoylpyridine thiosemicarbazone (H2Bz) and its  
N(4)-methyl (H2Bz4Me) and N(4)-phenyl (H2Bz4Ph) (Figure 1.14) derivatives were 
tested against MCF-7 (human breast adenocarcinoma), TK-10 (human renal 
carcinoma) and UACC-62 (human melanoma) tumour cell-lines. Both the ligands and 
complexes were tested. The ligands displayed lower values of GI50 (concentration 
required to reduce the growth of treated cells to half that of the untreated cells) and 
LD50 (median lethal dose required to kill 50% of the treated cells) than the 
complexes. Ligand H2Bz4Ph was found to be the most active. In some cases, 
however, lower lethal doses were required for the complexes. [Pd(2Bz4Ph)Cl] was 
found to be the most promising complex.41 
 
 
            
 
 
                             
 
                
        i                                             ii                                            iii 
 
Figure 1.14: Pd(II) complexes derived from 2-benzoylpyridine thiosemicarbazone  
i) [Pd(2Bz)Cl] ii) [Pd(2Bz4Me)Cl] iii) [Pd(2Bz4Ph)Cl] 
 
 
Palladium(II) chlorido (Figure 1.15) and bromido complexes of 2-acetylpyridine  
N(4)-methyl (HAc4Me), N(4)-ethyl (HAc4Et) as well as N(4)-phenyl (HAc4Ph) 
thiosemicarbazones were evaluated for their activity by measuring their ability to 
inhibit DNA synthesis. The complexes were found to exhibit activity against P388 and 
L1210 leukaemia cell cultures. The results revealed that the activity of the complexes 
are different to that of the ligands, which suggests independent cytotoxic properties. 





















Figure 1.15: Pd(II) complex derived from 2-acetylpyridine thiosemicarbazone-N-Me 




Cyclopalladated complexes derived from α-diphenyl ethanedione 
bis(thiosemicarbazone) and α-diphenyl ethanedione bis(4-ethylthiosemicarbazone) 
were evaluated for potential cytotoxic activity. The cytotoxic activities of the ligands 
and complexes were tested against human A2780 and A2780cisR ovarian carcinoma 
cell-lines and the ligands were found to display higher activity compared to the 
complexes. The lack of activity displayed by the palladium complexes is probably 
attributed to the presence of four bulky phenyl groups which may sterically hinder 
metal–DNA interactions.43  
 




The effect of 2-acetylpyridine thiosemicarbazone (AcTSC) Pt(II) derivatives,  
[Pt(AcTSC)2]·H2O,  [Pt(AcTSC)Cl] and [Pt(HAcTSC)2]Cl2·2H2O against leukaemia 
P388 cells was investigated. It was found that [Pt(AcTSC)2]·H2O induced the greatest 
antitumour effects, while [Pt(AcTsc)Cl] and [Pt(HAcTsc)2]Cl2·2H2O displayed 
marginal effects. The complexes also display decreased toxicity in comparison to the 
free ligands.44 
 
Reaction of Na2[PtCl4] with 2-acetylpyridine thiosemicarbazone (HAcTSC) in various 
stoichiometric amounts afforded three platinum complexes [Pt(AcTSC)Cl] (Figure 
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leukaemia P388. [Pt(AcTSC)2] was found to be the most effective in inducing 











Pt(II) complexes derived from 3,5-diacetyl-1,2,4-triazol bis(4-
phenylthiosemicarbazone) (H5L
1), 3,5-diacetyl-1,2,4-triazol bis(thiosemicarbazone) 
(H7L
2), 3,5-diacetyl-1,2,4-triazol bis(4-methylthiosemicarbazone) (H5L
3) and 3,5-
diacetyl-1,2,4-triazol bis(4-ethylthiosemicarbazone) (H5L
4) were evaluated in vitro for 





4)]2 were screened against human A2780 and A2780cisR 
epithelial ovarian carcinoma cell-lines for their cytotoxic activity. The IC50 values 
obtained were found to be comparable to that of cisplatin.46 Figure 1.17 displays the 
molecular structures of [Pt(µ-H3L
1)]2 (Figure 1.17.i) and [Pt(µ-H3L
3)]2 (Figure 1.17.ii).  
 
                          i          ii 
Figure 1.17: Molecular structures of dimeric complexes i) [Pt(µ-H3L
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A neutral ruthenium vitamin K3 derived thiosemicarbazone complex of the form  
[Ru(η6-p-cymene)(K3TSC)Cl2] (Figure 1.18) was evaluated for its in vitro cytotoxic 
activity against a panel of cancer cell-lines including human adenocarcinoma (HeLa), 
human myelogenous leukaemia (K562), human malignant melanoma (Fem-X), 
human breast carcinoma (MDA-MB-361 and MDA-MB-453) and normal cells. The 
complex showed low to moderate activity with an IC50 = 152.10 µM for the Fem-X 
cells and an IC50 = 101.84 µM for the MDA-MB-361 cells. Against HeLa, K562 and 
MDA-MB-453 cell-lines, the complex exerted moderate dose dependent 
antiproliferative activity, with IC50 values of 62.50, 71.26 and 62.46 µM, respectively. 
The complex was more active against the normal control cells, with an IC50 = 61.10 
µM for non-stimulated resting peripheral blood mononuclear cells (PBMC) and IC50 = 

















Figure 1.18: A neutral ruthenium vitamin K3 derived thiosemicarbazone complex of the form 
[Ru(η6-p-cymene)(K3tsc)Cl2] 
 
A series of half-sandwich arene ruthenium complexes (Figure 1.19) containing 
bidentate thiosemicarbazone ligands have also been evaluated for potential 
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colorectal carcinoma cells (HCT-116 and HT-29). The compounds have the general 
formula [Ru(η6-p-cymene)(R-ATSC)Cl]X (ATSC = 9-anthraldehyde 
thiosemicarbazone, R = H, CH3 or C6H5; and X = Cl
- or PF6
-). The complexes show 
good cytotoxic profiles against MCF-7 and MDA-MB-231 as well as HCT-116 and 
HT-29 cell-lines. All the complexes displayed moderate cytotoxic potencies against 
all cell-lines. The complex where R = CH3 and X = Cl
- was the most active against all 
cell-lines. It is also observed that as the R group increases in size, there is an overall 
decrease in potency of the compound. Another observation is that the compounds 








R = H, CH3, C6H5; X = Cl, PF6 
 
Figure 1.19: Complexes of the general formula [Ru(R-ATSC)(η6-p-cymene)Cl]X  
investigated as potential anticancer agents 
 
The reaction of [Ru(dppb)(H2O)Cl3] (dppb = 1,4 bis(diphenylphospine)butane) with  
2-benzoylpyridine thiosemicarbazone (H2Bz) and its N(4)-methyl (H2Bz4Me) and 
N(4)-phenyl (H2Bz4Ph) derivatives gave three complexes i.e. [Ru(dppb)(H2Bz)Cl]Cl, 
[Ru(dppb)(H2Bz4Me)Cl]Cl and [Ru(dppb)(H2Bz4Ph)Cl]Cl. Cytotoxic studies were 
carried out using these compounds on the MCF-7, TK-10 and UACC-62 human 
tumour cell-lines. The precursor [Ru(dppb)(H2O)Cl3] exhibits cytocidal activity against 
the three cell-lines. H2BzDH, H2Bz4M, and [Ru(dppb)(H2Bz4M)Cl]Cl show a 
selective cytocidal effect against the UACC-62 cell-line.49 
 
Two ruthenium(II) triphenylphosphine complexes of 2-acetylpyridine N4,N4-
dimethylthiosemicarbazone (HL1) and phenanthrenequinone thiosemicarbazone 
(HL2), namely [Ru(L1)(PPh3)2Cl] and [Ru(L
2)(PPh3)2Cl], were obtained. Also treatment 
of [Ru(DMSO)4Cl2] with HL
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highly water-soluble complex  of the form [Ru(L1)(HPTA)2Cl]Cl2·C2H5OH·H2O (Figure 
1.20). The complex shows strong antiproliferative activity in the low micromolar 
concentration range against the ovarian carcinoma cell-line, 41M (IC50 = 0.87 µM) 
and moderate activity in the breast cancer cell-line, SK-BR-3 (IC50 = 39 µM). The 
activity of the compound is 6.5- and 5.4-times higher at pH = 6.0 than at  
pH = 7.4 against the non-small cell lung cancer cell-line, A549 and the colon 








Figure 1.20: A water-soluble complex with pH-dependent antiproliferative activity 
 
 
1.6. Synthesis and applications of some dithiosemica rbazone complexes  
The synthesis and anticancer abilities of dithiosemicarbazone complexes containing 
palladium, platinum and ruthenium have not been fully explored in literature. 
Generally, platinum group metal complexes of these ligands are scarce. Here follows 
some examples of dithiosemicarbazone complexes containing various transition 
metals.  
 
Ethylene-bridged dithiosemicarbazone copper complexes were synthesised by 
Gringas et al.51 These complexes were tested as antifungal agents against the 
cellulotic microorganism Chaetomium globasum and were found to exhibit activity.51 
Antibacterial studies were carried out on various piperazine-bridged titanium and 
zirconium complexes (Figure 1.21). These complexes were found to display 
antifungal activity. In addition to this, the zirconium complexes exhibited better 
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  M = Ti, Zr; X = Cl, NO2 
 
Figure 1.21: Structures of binuclear titanium(IV) and zirconium(IV) complexes  
of piperazine dithiosemicarbazones 
 
Various other dithiosemicarbazones containing zinc,53 lanthanum(III),54 
praseodymium(III),54 nickel,23 cobalt23 and copper23 have been synthesised but 
investigation of their potential applications has not been fully exploited. Dilworth et 
al.53 reported on the synthesis of various bimetallic zinc thiosemicarbazone 
complexes with rigid aromatic linkers (Figure 1.22) as well as non-rigid linkers.   







































ii   
      R = Me, Ph 
 
Figure 1.22: Examples of rigid bimetallic thiosemicarbazone complexes synthesised by 
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The synthesis of La(III) and Pr(III) complexes of the type [(Ln(L)(H2O)Cl]2, where  
Ln = La(III) or Pr(III) and L = piperazine dithiosemicarbazone ligands derived from 
benzaldehyde, 4-nitrobenzaldehyde and 2-methoxybenzaldehyde, was reported by 
Tripathi et al.54 These complexes were prepared and characterised using common 
spectroscopic techniques.54 
 
Bis(di-2-pyridyl ketone) dithiosemicarbazone complexes containing cobalt(II), 
nickel(II) and copper(II) have been prepared and reported by West et al.23 The 
dithiosemicarbazones were prepared from piperazine and ethylene 
dithiosemicarbazides and subsequently complexed to afford bi- (Figure 1.23.i, ii and 




























































































                                 M = Co(II), Ni(II); R = piperazine, N, N’-dimethyl ethylenediamine 
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More recently, novel dithiosemicarbazone palladium(II) complexes derived from 
various salicylaldehydes (Figure 1.24) have been synthesised and characterised, 
however, the study of their biological properties have proved to be problematic due to  
their low solubility in DMSO and water. Only their respective ligands were thus 
evaluated for activity.55 The ligands displayed moderate activity against various 
oesophageal cancer cell-lines (WHCO1, WHCO5 and WHCO6) with IC50 values 
ranging between 1.24 and 30.97 µM. The insolubility of these Pd(II) complexes may 
be attributed to the incorporation of PPh3 as part of these complexes.
55  
 












PPh3 PPh3R R  
 
X = C2H4, C4H4; R = H, 
tBu, OMe 
 
Figure 1.24: Novel Pd(II) salicylaldiminato dithiosemicarbazone complexes  
 
1.7. Aims and Objectives 
1.7.1. Aims 
Due to the vast biological properties that most thiosemicarbazone compounds 
possess, as discussed in this chapter, it would be interesting to investigate the 
structural and biological properties of various thiosemicarbazone platinum group 
metal (PGM) complexes. Studying the biological properties of some palladium 
compounds has previously been problematic due to their low water-solubility.55 This 
study therefore aims to synthesise a range of mono-, di- and trinuclear 
thiosemicarbazone compounds by incorporating a water-soluble phosphine ligand, 
1,3,5-triaza-7-phosphaadamantane (PTA), as part of these complexes to investigate 
their potential anticancer activity  in mammalian oesophageal cancer cells as well as 
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1.7.2. Specific Objectives 
• To synthesise a series of monothiosemicarbazone salicylaldimine ligands 
(Figure 1.25.i) containing various aryl substituents for complexation. 
 
• To prepare similar dithiosemicarbazone salicylaldimine ligands (Figure 1.25.ii) 
containing an ethylene spacer from ethane-1,2-dithiosemicarbazide and 
various salicylaldehydes. Based on our previous work, it was found that 
complexes containing alkyl bridging moieties displayed better solubility than 
those with bridging aryl moieties.55 Dilworth et al.53 have also attempted the 
synthesis of dithiosemicarbazones with longer chain lengths such as propane, 
however isolation of the product was problematic and therefore we have 
decided to explore the activity of compounds containing ethylene spacers 
only. 
           i      ii 
                               R = H; 3-tBu; 3-OMe; 5-Cl 
 
Figure 1.25: Thiosemicarbazone ligands to be synthesised in this study 
 
• In addition to the above mentioned thiosemicarbazone ligands, the preparation 
of a new kind of thiosemicarbazone system is investigated using various 
salicylaldehydes. This system comprises three thiosemicarbazone moieties 
linked by their amino nitrogen atoms to a nitrogen core by ethyl linkers, thus 
affording trithiosemicarbazone ligands (Figure 1.26). Similar ligand systems 
have displayed promising antimalarial activity against a chloroquine-resistant 
W2 strain of the parasite P. falciparum.56 Preparation of these compounds will 
allow us to compare the effect of increasing size on biological activity. Reports 
have shown that larger molecules are able to penetrate and be retained inside 
tumour cells more efficiently than healthy cells.57 This is mainly attributed to 
the Enhanced Permeability and Retention (EPR) effect which is experienced 
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compounds is carried out by adapting methodologies previously used by 








                 R = H; 3- tBu; 3-OMe; 5-Cl 
 
Figure 1.26: Novel trithiosemicarbazone ligands investigated in this study 
 
These specific ligands have been chosen in order to investigate the effect of 
increasing size and the number of thiosemicarbazone moieties on biological activity.   
  
• To complex these ligands with cis-[Pd(PTA)2Cl2]58 and cis-[Pt(PTA)2Cl2]59 to 
afford the corresponding mono- (Figure 1.27.i), di- (Figure 1.27.ii) and 
trinuclear (Figure 1.27.iii) complexes.   
 
The rationale behind the synthesis of these specific complexes stems from the 
hypothesis that using water-soluble phosphine ligands such as 1,3,5-triaza-7-
phosphaadamantane (PTA), would potentially increase the overall solubility of 
these compounds in a DMSO-water medium (medium in which the biological 
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  R = H, 3-tBu, 3-OM, 5-Cl; M = Pd, Pt 
 
Figure 1.27: Thiosemicarbazone complexes investigated in this study 
 
• To prepare a series of mono- (Figure 1.28.i) and dinuclear (Figure 1.28.ii) 
ruthenium thiosemicarbazone complexes using appropriate 
thiosemicarbazone ligands for their reaction with arene-ruthenium precursors 
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• Characterisation of the proposed compounds is carried out using Nuclear 
Magnetic Resonance spectroscopy (NMR), Infrared spectroscopy (IR), 
Elemental Analysis (EA) as well as Electrospray Ionisation Mass Spectrometry 
(ESI-MS). Isolation of some of the complexes as crystals suitable for single 
crystal X-ray diffraction to provide insight into their modes of coordination.  
 
• Lastly, to investigate the in vitro biological properties of selected ligands and 
complexes against the mammalian oesophageal cancer cell-line, WHCO1 and 
against the paraiste T. Vaginalis.  
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Thiosemicarbazones exhibit various biological properties including 
antimalarial, antibacterial and antitumoural.1-3 Salicylaldimine 
thiosemicarbazones (TSCs) have exhibited antiproliferative activity on a range 
of tumour cell-lines and are therefore candidates as potential tumour agents.4 
Salicylaldimine thiosemicarbazones are Schiff-base compounds formed from 
condensation of various substituted salicylaldehydes and thiosemicarbazide 
precursors. The main objectives of this study were to synthesise a range of 
salicylaldimine TSC compounds for complexation to various platinum group 
metals (Chapter 3), in order to evaluate their biological activity against 
WHCO1 oesophageal cancer cells and T. vaginalis (Chapter 5). Previous 
investigation of the biological activity of mono- and dithiosemicarbazones 
derived from salicylaldehydes displayed promising results.5,6 The preparation 
of a new thiosemicarbazone system has been investigated in this study. This 
system comprises of three thiosemicarbazone moieties linked by their amino 
nitrogen atoms to a nitrogen core by ethyl linkers. We have therefore coined 
the term “trithiosemicarbazones” to describe these compounds. These 
compounds were prepared in order to compare the effect of increasing size 
on biological activity. This chapter describes the synthesis and 
characterisation of various mono-, di- and trithiosemicarbazone 
salicylaldimine ligands for complexation. The anticancer properties of these 
ligands have also been evaluated and are discussed in Chapter 5.    
 
2.2. Preparation of monothiosemicarbazones (1 – 4) 
2.2.1. Synthetic approach and physical properties 
Four monothiosemicarbazone salicylaldimine compounds (1-4) were 
synthesised by simple Schiff-base condensation reactions between various 
functionalised salicylaldehydes (salicylaldehyde, 3-methoxy salicylaldehyde,  
3-tert-butyl-salicylaldehyde and 5-chlorosalicylaldehyde) and 
thiosemicarbazide (Scheme 2.1). The reactants were refluxed in ethanol for 
approximately 6 hours, yielding white solids that precipitate from solution upon 
cooling of the reaction mixture. The products were washed with cold ethanol, 
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these ligands were determined and found to be thermally stable, which 
compares favourably with literature.5,7-9  




                                        
     
   R = H (1), 3-OMe (2), 3-tBu (3), 5-Cl (4) 
 
Scheme 2.1: Preparation of salicylaldimine monothiosemicarbazones 
 
2.2.2. Characterisation  
1H Nuclear Magnetic Resonance Spectroscopy  
The NMR spectra of these ligands were recorded in DMSO-d6. Figure 2.1 
displays an example of a typical 1H NMR spectrum of one of these 
monothiosemicarbazones. Some 1H NMR assignments here and elsewhere 
were made using 2D Correlation spectroscopy (COSY). Generally these 
ligands exhibit similar trends on comparison of their spectra. The most 
important signal to note is the imine signal. The imine proton signals occur as 
sharp singlets in the region of 8.26-8.42 ppm. This therefore confirms 
condensation of the respective salicylaldehydes with thiosemicarbazide. Also 
worth noting is the position of the signal for the hydrazinic proton. Signals for 
the hydrazinic protons occur as singlets relatively downfield in their respective 
spectra, between 11.25 and 11.36 ppm. Signals for the phenolic protons are 
generally broad singlets that occur between 9.16 and 10.03 ppm. Peaks for 
the terminal amino protons approximately occur at 7.90 ppm and are 
observed as one singlet in the spectra of compounds 3 and 4. In the case of 1 
and 2, each terminal amino proton signal is observed as a separate singlet. 
This is due to restricted rotation of the amino group about the C-N bond axis 
caused by delocalization of the lone pair of electrons of the NH2 nitrogen 
(Figure 2.2). This phenomenon has been observed in literature.10-12 





































ketone compounds. An equilibrium exists between thione and thiolate form. 
The thione form predominates as the bond energy of the C=N compared to 




Figure 2.1: 1H NMR spectrum of salicylaldimine monothiosemicarbazone (1) 
 
The aromatic protons are observed in the region of 6.78-7.92 ppm. The 
protons of the methyl substituents for compounds 2 (OMe) and 3 (tBu) are 




Figure 2.2: Delocalization of terminal nitrogen lone pairs  
 
13C{1H}Nuclear Magnetic Resonance Spectroscopy  
The 13C{1H} NMR spectrum of each compound displays the expected number 
of carbon signals, further supporting the structure and composition of these 
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the aid of 2D Heteronuclear Single Quantum Coherence (HSQC) 
spectroscopy. Signals for the thione carbon atoms occur between 177.76 and 
177.99 ppm. The imine carbon signals appear in the region of 137.60-147.01 
ppm. Signals for the phenolic carbon atoms are observed between 154.98-
156.25 ppm in the case of 1, 3 and 4. The phenolic carbon signal of 
compound 2 is observed at 147.83 ppm, which is further upfield in comparison 
to the other three compounds. This is mainly attributed to the electronic 
effects of the electron-donating methoxy group.     
 
Infrared Spectroscopy  
Further supporting evidence of the synthesis of these ligands is observed in 
the infrared (IR) spectra of these compounds. Particular attention is drawn to 
the appearance of absorption bands in the region of 1614-1657 cm-1. These 
bands represent the imine ν(C=N) stretching frequencies of the 
monothiosemicarbazones, confirming Schiff-base condensation of the 
respective precursors. The ν(O-H) and ν(N-H) bands for the phenolic oxygens 
and hydrazinic nitrogens, respectively, are observed in the region of 3100-
3400 cm-1. These frequencies are in accordance with literature data for the 
same type of compounds.4 The ν(C=S) absorption bands appear between 830 












Figure 2.3: IR spectrum of salicylaldimine monothiosemicarbazone (1) 
 
The spectroscopic data obtained thus supports the preparation of these 





















1H                         13C 
-HC=N-    -NH-       -C=N-     -C=S 
IR (cm -1) 
 
-C=N- 
1 H 8.40 11.36 140.02 177.76 1615 
2 3-OMe 8.42 11.29 139.76 177.78 1622 
3 3-tBu 8.26 11.25 147.01 177.94 1614 
4 5-Cl 8.30 11.30 137.60 177.99 1657 
 
2.3. Preparation of dithiosemicarbazones (6-9) 
2.3.1. Synthetic approach and physical properties 
Salicylaldimine dithiosemicarbazone ligands may be prepared by two routes. 
One method involves a three step synthetic sequence in which methyl 
hydrazinecarbodithioate (Scheme 2.2) is prepared and condensed with 
aldehydes, after which the S-methyl group of the compound obtained is 
displaced by the desired amine by means of a nucleophillic addition reaction 
giving rise to the desired dithiosemicarbazone. Although this route has been 
successfully utilised by Klayman et al.,13 it was decided to utilise a more viable 












Scheme 2.2: One route towards the preparation of thiosemicarbazones 
CS2  +  H2NNH2



































1) 2 eq. CS2/NaOH/H2O




















































Four ethylene-bridged salicylaldimine dithiosemicarbazone derivatives were 
synthesised using methodology outlined in Scheme 2.3. The procedure 
involves the synthesis of ethane-1,2-dithiosemicarbazide (5) utilising the 
method outlined by Dilworth et al.14 The method involves the preparation of 
the dithiosemicarbazide from ethylenediamine via a diacid precursor (Scheme 
2.3). The diacid formed is then treated with excess hydrazine hydrate which 
displaces the carboxylic acid moiety by nucleophillic addition to the 
thiocarbonyl forming the desired thiosemicarbazide. The product is obtained 
as a white powder that precipitates from solution in good purity but in a low 

















R = H (6), 3-OMe (7), 3-tBu (8), 5-Cl (9) 
 
Scheme 2.3: Method employed to prepare the desired  
salicylaldimine dithiosemicarbazones 
 
Due to the poor solubility of the dithiosemicarbazide in most organic solvents 
with the exception of DMSO and DMF, condensation of 5 with the afore-
mentioned salicylaldehydes were carried out in DMF to give rise to the 
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were therefore isolated by means of precipitation with water.6 These Schiff-
base reactions can be carried out in alcoholic solvents but require extended 
reaction time periods for completion due to the low solubility of 5 in these 
solvents. Melting points of compounds 6-8 agree with literature,6 while the 
new 5-chloro dithiosemicarbazone derivative (9) displays similar thermal 
stability in comparison to the other members of the series. 
                                                                                      
2.3.2.  Characterisation 
1H Nuclear Magnetic Resonance Spectroscopy  
Evidence for the preparation of dithiosemicarbazones 6-9 is clearly depicted 
in the 1H NMR spectra of these ligands. Figure 2.4 displays the 1H NMR 
spectrum of ligand 6. These dithiosemicarbazone ligands possess a 2-fold 
symmetry about the ethane bridge and we therefore see one set of signals for 
equivalent hydrogens. As seen with the spectra of the 
monothiosemicarbazones, the imine signals appear between 8.29 and 8.41 
ppm. The signals attributed to the aliphatic protons of the ethylene bridge 
appear as a singlet in the region of approximately 3.80 ppm. Peaks for the 
amino protons adjacent to the ethylene spacer appear as a singlet between 
8.56 and 8.74 ppm. Signals attributed to the hydrazinic protons (which are the 
NH protons adjacent to the imine moiety) appear downfield in a region similar 
to their monomeric counterparts (11.41-11.56 ppm). Signals for the methyl 
protons corresponding to the methoxy substituent of 7 is observed at 3.80 
ppm, while signals for the tBu protons of 8 are observed at 1.39 ppm.   
 
13C{1H} Nuclear Magnetic Resonance Spectroscopy  
The 13C{1H} NMR spectra of these dithiosemicarbazone compounds display 
the appropriate number of signals in each case. The spectrum of 9 was of 
particular importance since it is a new ligand and has not been reported in 
literature. It displays all the expected signals, with the signal for the thione 
carbon appearing at 178.11 ppm and the imine carbon signal at 138.34 ppm. 
This is in close agreement with the shifts of the corresponding 
monothiosemicarbazone derivative (177.99 and 137.60 ppm). The remaining 




















177.88 ppm and 139.44-147.66 ppm for their thione and imine carbon atoms, 
respectively. Signals for the phenolic carbon atoms are found in the range of 
155.85-156.22 ppm for compounds 6, 8 and 9, while the same signal is found 




















Figure 2.4: 1H NMR spectrum of salicylaldimine dithiosemicarbazone (6) 
 
Infrared Spectroscopy  
Absorption bands in the region of 1598-1671 cm-1 are assigned to the ν(C=N) 
stretching frequencies of these compounds. Absorption bands for the ν(C=S) 
frequencies are observed at lower energies in comparison to the 
monothiosemicarbazones, with the exception of compound 8, which occurs at 
a slightly higher frequency than its monomeric counterpart. Absorption bands 
in the region of 3000-3300 cm-1 are attributed to the ν(O-H) and ν(N-H) 
stretching frequencies for the phenolic, hydrazinic and amino moieties. Table 





















































1H                              13C 
-HC=N-          -NH-       -C=N-       -C=S 
IR (cm -1) 
 
-C=N- 
6 H 8.39 11.47 139.64 177.23 1618 
7 3-OMe 8.41 11.50 139.44 177.23 1671 
8 3-tBu 8.29 11.41 147.66 177.88 1598 
9 5-Cl 8.36 11.56 138.34 178.11 1616 
 
Elemental Analysis and Mass Spectrometry  
Microanalysis of these compounds was found to be consistent with the 
calculated values. Electrospray Ionisation (ESI) mass spectrometry was 
carried out on compound 9. The spectrum displayed a base peak 
corresponding to the molecular ion at m/z 485 ([M]+). 
 
2.4. Preparation of trithiosemicarbazones (11-14) 
2.4.1. Synthetic approach and physical properties 
Targeted therapy, where drugs selectively interact or harm abnormal cells, is 
an area of great importance. This kind of therapy also results in reduced side 
effects in comparison to other treatments. Incorporation of drugs onto 
polyamines may improve their selectivity towards tumour cells. Polyamines 
are naturally occurring agents that are found in large amounts in mammalian 
cells and are essential for cell growth.15 Previous studies carried out on these 
systems reveal that these agents are able to transport cytotoxic drugs into 
tumour cells.16 Tumour cells import polyamines by means of a polyamine 
transporter (PAT) in order to sustain their growth. The transporter is able to 
tolerate modified polyamines, therefore drug incorporated polyamines are 
able to penetrate the tumour cells via the PAT.17  
 
Since thiosemicarbazones possess cytotoxic properties, they serve as good 

















1) 3 eq NaOH/H2O
2) 3 eq CS2























































chapter, another advantage in using larger systems is that these compounds 
are able to be retained more efficiently in tumour cells than in normal cells. 
This phenomenon is known as the “Enhanced Permeability and Retention” 
(EPR) effect.18 Based on this, the preparation of a new class of 
thiosemicarbazone compound has been investigated in this study.  
 
Salicylaldimine TSC moieties have been incorporated onto  
tris(2-aminoethyl)amine yielding  trimeric compounds. These compounds 
have been termed trithiosemicarbazones because they possess three 
thiosemicarbazone moieties linked to a central core (in this case a nitrogen 
atom) by their amino nitrogen atoms. The preparation of these compounds 
was carried out using chemistry similar to that of the previously mentioned 
dithiosemicarbazones, adapting the chemistry for the preparation of ethane-
1,2-dithiosemicarbazide accordingly (Scheme 2.4). This particular method 
involved the preparation of tris(2-aminoethyl) thiosemicarbazide (10) 


















             R = H (11), 3-OMe (12), 3-tBu (13), 5-Cl (14) 
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A solution of the tris(2-aminoethyl)amine in water was treated with carbon 
disulfide, sodium chloroacetate and HCl, presumably affording a triacid 
precursor, which is further reacted with hydrazine hydrate to deliver the 
required product. The trithiosemicarbazide was obtained as an oily-like 
substance and was dried at roughly 110 °C. Upon coo ling the product 
solidifies to give rise to a yellowish powder in a yield of 23%. It does however 
absorb moisture from the atmosphere upon prolonged exposure.  
 
Further reaction of 10 with salicylaldehyde, 3-methoxysalicylaldehyde, 3-tBu-
salicylaldehyde and 5-chlorosalicylaldehyde in ethanol or methanol resulted in 
the desired trithiosemicarbazone ligands (11-14). Addition of water to the 
resulting solution gives rise to yellow powders, with the exception of 13, which 
is obtained as a yellow oil.  
 
These trithiosemicarbazone ligands display enhanced solubility in most 
organic solvents (ethanol, methanol, methylene chloride) in comparison to 
their mono- and dithiosemicarbazone counterparts at ambient temperature. 
Ligand 13 was isolated in a different manner, due to its inability to precipitate 
from solution. In this particular case the solvent (MeOH) was completely 
removed giving rise to a yellow oil, which was re-dissolved in approximately 
20 cm3 of methylene chloride. The extract was washed several times with 
water to remove any unreacted aldehyde. The methylene chloride was 




1H Nuclear Magnetic Resonance Spectroscopy  
The proton NMR spectra of the trithiosemicarbazone compounds bear great 
similarity to the spectra of their mono- and dithiosemicarbazone counterparts. 
The spectrum of compound 12 is depicted in Figure 2.5. Similar to the 
dithiosemicarbazones, the trithiosemicarbazones possess a 3-fold symmetry 
and thus one signal is seen for each equivalent proton. Signals for the imine 























appear in the range of 11.34-11.50 ppm. Signals for the phenolic protons are 























Figure 2.5: 1H NMR spectrum of 3-methoxy trithiosemicarbazone (12) 
 
 
The major difference between the spectra of these compounds and the mono- 
and di- derivatives is attributed to the presence of the methylene protons of 
the alkyl bridges. These signals are found at approximately 2.85 and 3.75 
ppm, for Ha and Hb respectively.  
 
 
13C{1H) Nuclear Magnetic Resonance Spectroscopy  
The methylene carbon signals are found between 41.57-42.60 ppm (Cb) and 
between 52.50-53.42 ppm (Ca). Signals for the thione carbon atoms appear in 
the region of 176.88-177.64 ppm, while the imine carbon atom signals are 
found between 137.28 and 140.00 ppm. The phenolic carbon signals are 
observed between 154.98-157.15 ppm for 11, 13 and 14. The same signal for 
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other ligands of this particular series. This is in accordance with the mono- 
and dithiosemicarbazone derivatives. 
 
Infrared Spectroscopy  
Absorption bands for the imine stretching frequencies are observed in the 
region between 1605 and 1650 cm-1. These bands further support 
condensation of the respective salicylaldehydes with 10. Absorption bands for 
the ν(C=S) frequencies are found at similar frequencies in comparison to the 
dithiosemicarbazones. Similar energies are also observed for the ν(O-H) and  
ν(N-H) stretching frequencies as the mono- and dithiosemicarbazones.    




Spectroscopic data obtained for trithiosemicarbazones (11-14) 
Compound R 
NMR (ppm) 
                     1H                           13C 
  -HC=N-       -NH-      -C=N-       -C=S 
IR (cm -1) 
 
-C=N- 
11 H 8.38 11.34 140.00 177.64 1620 
12 3-OMe 8.43 11.47 139.16 176.88 1605 
13 3-tBu 8.27 11.39 147.19 177.28 1651 
14 5-Cl 8.35 11.50 137.28 177.02 1618 
 
Elemental Analysis and Mass Spectrometry 
The elemental analysis obtained for these ligands was in agreement with the 
expected values. The data obtained for 11 was consistent with the calculated 
values of this compound which attests to its purity. Mass spectrometry also 
supported the integrity of these compounds. Compound 10 displayed a base 
peak at m/z 369 corresponding to the [M+H]+ ion. Compounds 11, 12 and 14 
all displayed base peaks in their respective spectra, corresponding to their 
molecular ions at m/z 681, 771 and 785, respectively. The spectra of 
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with the molecular weight of the ligand. A base peak at m/z 489 corresponds 
to the fragment [M+3ACN+2H]2+.  
 
 2.5. Conclusion  
Four new trithiosemicarbazone ligands (11-14) and one dithiosemicarbazone 
ligand (9) was prepared and characterised using common analytical and 
spectroscopic techniques. The synthesis of these compounds is clearly 
depicted in their spectroscopic data. In addition to this, microanalysis and 
mass spectrometry further support their integrity. Although the mono-, di- and 
trithiosemicarbazone compounds are somewhat different structurally, their 
spectroscopic similarities are vast. These compounds were found to be 
extremely stable in air and at elevated temperatures. The 
trithiosemicarbazone ligands display better solubility than their mono- and 
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Synthesis and Characterisation of 
















The chemistry of transition metal complexes of thiosemicarbazones has 
received considerable attention due to their diverse activities.1,2 The biological 
activity of many thiosemicarbazones often increase on coordination to a 
particular metal ion. Lipophilicity (which controls the rate of entry of a 
particular molecule into a cell) is sometimes also altered by metal 
coordination. Certain side effects can also be reduced upon complexation of 
the thiosemicarbazone ligand and in some cases the complexes display 
activities not exhibited by the free ligand.3 Combining thiosemicarbazones 
with metals such as palladium(II) and platinum(II) results in synergistic 
inhibition of tumour growth and may lead to improvements in its effectiveness 
as chemotherapeutic agents.4-6                         
 
Although many thiosemicarbazones exhibit activity, most of them exhibit poor 
solubility in a number of solvents, including water. In order to evaluate the 
activity of these compounds, a sample is often solubilised in DMSO and 
diluted accordingly. If the compound possesses low water-solubility, 
precipitation often occurs from the culture medium during in vitro evaluation, 
which may result in unreliable and non-reproducible data. Incorporation of 
water-soluble groups may enhance the solubility in water or may assist in the 
prevention of precipitation of the compounds when being evaluated in water. 
A water-soluble ligand that has received attention in the field of catalysis as 







Figure 3.1: PTA, a water-soluble phosphine ligand used in  
catalysis and biological studies 
 
A wide range of metal complexes bearing this particular phosphine have been 










CHAPTER 3                                  Salicylaldiminato TSC complexes 
 
 46
ruthenium, rhodium, platinum and palladium have been utilised for 
coordination.7 Trans-[Pt(SC4H3N2)2(PTA)2], trans-[Pt(SC5H4N)2(PTA)2] and 
[Au(SC4H3N2)(PTA)] are examples of complexes that contain the PTA ligand.
8 
These compounds were synthesised and their cytotoxicity tested against 
ovarian, colon, renal, breast, lung and melanoma cancer cell-lines and 
displayed considerable cytotoxic activities.8 [Ru(η6-arene)(PTA)Cl2] complexes 
(RAPTA-type) inhibit secondary tumour growth (a tumour that has spread 
from its original (primary) site of growth to another site) in various cell-lines.9  
Pt(II) complexes bearing PTA and thiocarbamate esters such as  
trans-[Pt(SC(OMe)=NC6H4R)2(PTA)2] (R = H, Cl, OMe, NO2, Me) were tested 
in vitro in four human cancer cell-lines (CH1, HT29, A549, SK-OV-3) using  
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. 
IC50 values obtained for some of these complexes were lower when compared 
to cisplatin.10 Considering this and several other examples, the use of PTA as 
a co-ligand is therefore supported for the use in medicinal chemistry and 
therefore can be incorporated as part of thiosemicarbazone complexes. 
 
3.2.  Pd and Pt salicylaldiminato PTA monothiosemicarbazones (18-25) 
3.2.1.  Synthetic approach and physical properties 
With the aim of synthesising Pd(II) and Pt(II) thiosemicarbazone complexes 
containing PTA, the monothiosemicarbazones mentioned in Section 2.2 were 
reacted with two metal precursors of the general formula cis-[M(PTA)2Cl2], 
where M = Pd or Pt. Treatment of 1 equivalent of  
cis-[Pd(COD)Cl2] (15)11 with 2 equivalents of PTA in methylene chloride and 
stirring for 5 hours at room temperature, gave rise to cis-[Pd(PTA)2Cl2] (16).12 
The product was obtained as a yellow powder in 96% yield.  
Cis-[Pt(PTA)2Cl2] (17) was prepared by a metathesis reaction between 1 
equivalent of K2[PtCl4] and 2.1 equivalents of PTA in a mixture of ethanol and 
water at 60 °C for approximately 2 hours, giving ri se to an off-white powder in 
a yield of 78%.13  
 
Reaction of these metal precursors with the respective 
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(Scheme 3.1) afforded the required Pd(II) (18-21) and Pt(II) (22-25) 
salicylaldiminato monothiosemicarbazones in high yields. These complexes 
(18-25) were isolated as yellow amorphous solids. The use of triethylamine 
promotes coordination of the metal in an O-N-S tridentate manner following 
the abstraction of the phenolic proton in each ligand. This mode of 
coordination is well documented in literature for similar systems.14-17 These 
complexes (18-25) are soluble in DMSO but display low solubility in other 








     
18: R = H, M = Pd 22: R = H, M = Pt 
19: R = 3-OMe, M=Pd 23: R = 3-OMe, M=Pt 
20: R = 3-tBu; M =Pd 24: R = 3-tBu; M =Pt 
21:R = 5-Cl, M =Pd  25: R = 5-Cl, M =Pt 
 
Scheme 3.1: Synthesis of Pd and Pt salicylaldiminato monothiosemicarbazones 
 
3.2.2.   Characterisation 
1H Nuclear Magnetic Resonance Spectroscopy  
Due to the similarities between the palladium and platinum complexes, the 
discussion of their spectroscopic properties will be combined. Table 3.1 
highlights some 1H NMR data. Analysis of the data revealed that 
complexation of free ligands occurs in a dianionic manner through the thiolate 
sulfur and phenolic oxygen. This is supported by the absence of signals 
accounting for the phenolic and hydrazinic protons in the spectrum of each 
complex. Coordination of the sulfur in the thiolate form as opposed to the 
thione form is thus observed. There are two types of methylene protons 
present in the PTA ligand. One type is assigned to the P-CH2-N protons, 







2) 1 eq. cis-[M(PTA)2Cl2]
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the N-CH2-N moiety possess an AB spin system (giving rise to an AB spin 
pattern) and appear as two doublets, due to geminal coupling, at 4.50 ppm. 
One doublet corresponds to the three N-CHAx-N protons, while the other is 
observed for the three N-CHEq-N protons. This is consistent with other PTA 
transition metal complexes.18-20 
 
Table 3.1  










18 Pd H  8.21 13.18 
19 Pd 3-OMe  8.27 13.20 
20 Pd 3-tBu  8.28 13.48 
21 Pd 5-Cl  8.30 13.00 
22 Pt H  8.57 11.21 
23 Pt 3-OMe  8.51 11.24 
24 Pt 3-tBu  8.56 11.37 
25 Pt 5-Cl  8.55 11.11 
 
In both cases (Pd and Pt), the signal for the imine proton splits to form a 
doublet. This is expected if the metal centre coordinates to the azomethine 
nitrogen as well, supporting the notion of coordination in a tridentate manner. 
The splitting of imine signal into a doublet is attributed to coupling of the 
phosphorus nucleus (of the PTA ligand) to the nucleus of the imine proton 
situated four bonds away. This phenomenon is documented in literature for 
similar triphenylphosphine complexes.14-17 The coupling constants obtained 
for the Pd complexes range between 13.00 and 13.48 Hz, while the Pt 
complexes display J values ranging between 11.11 and 11.37 Hz (Table 3.1). 
The variance in coupling constants can be attributed to the difference in 
electronegativity or size of the two metals. When comparing the shifts of the 
complexes compared to their free ligands there are some noteworthy 
differences. In the case of the Pd(II) complexes, a shift of the imine signal 
























monothiosemicarbazones. In contrast, the Pt(II) complexes display shifts of 
these signals downfield (ca. 8.50 ppm). A typical 1H NMR spectrum for these 

















Figure 3.2: 1H NMR Spectrum of complex 18 
 
13C{1H} Nuclear Magnetic Resonance Spectroscopy 
13C{1H} NMR spectroscopy also aided in confirming the mode of coordination 
of these complexes. Overall the signals accounting for the phenolic carbon 
atoms appear to shift downfield for both the Pd(II) and Pt(II) systems upon 
coordination (156.00 ppm in the ligands vs 160.00 ppm in the complexes). 
This same phenomenon is observed for the azomethine carbon signals 
(140.00 ppm in the ligands vs 146.00 ppm in the complexes). In contrast to 
this, the signals corresponding to the thiolate carbon are found more upfield 
(172.00 ppm) in comparison to the free ligands (178.00 ppm) which is 
consistent with increased electron-density at the thiolato sulfur atom due to 
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31P{1H} Nuclear Magnetic Resonance Spectroscopy 
31P{1H} NMR spectroscopy was employed in order to monitor the shift of the 
31P signal upon complexation of the metal precursors. The phosphorus 
signals of the free cis-[Pd(PTA)2Cl2] (16) and cis-[Pt(PTA)2Cl2] (17) species 
are observed at -23.60 and -49.19 ppm, respectively. The latter also displays 
platinum satellites (1JPt-P = 3302.10 Hz) due to coupling to the spin active 
195Pt 
nucleus which has a natural abundance of 34%. Compounds 18-21 exhibit 
signals in the region of -40.00 ppm, while the corresponding Pt derivatives 
(22-25) display typical resonances at approximately -60.00 ppm. The Pt-P 
coupling constants observed for compounds 22-25 are consistent with the 
1JPt-P constant observed for the free cis-[Pt(PTA)2Cl2] precursor. Table 3.2 
provides some relevant data obtained for these complexes. 
 
Table 3.2 








        -C-S        -C=N- 
31P{1H}  
NMR (ppm) 
[1JPt-P  value 
(Hz)] 
18 Pd H  171.17 147.57 -40.70 
19 Pd 3-OMe  172.01 148.16 -39.37 
20 Pd 3-tBu  170.95 149.51 -43.77 
21 Pd 5-Cl  171.98 146.51 -40.06 
22 Pt H  172.56 145.90 -61.37  [3344.43] 
23 Pt 3-OMe  172.58 145.66 -56.80  [3334.90] 
24 Pt 3-tBu  172.40 147.81 -60.71  [3341.70] 
25 Pt 5-Cl  174.11 145.72 -58.07  [3338.67] 
 
Infrared Spectroscopy  
Infrared spectroscopy is another diagnostic tool used to confirm the mode of 
coordination occurring within molecules. Coordination of ligands 1-4 in the 
thiolate form implies that a second imine bond forms upon deprotonation of 
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observed in the infrared spectra of the complexes. The IR spectra do indeed 
reveal two absorption bands in the region between 1590 and 1655 cm-1 
attributed to the C=N stretching frequencies (Figure 3.3). Bands of higher 
frequency are observed between 1615 and 1653 cm-1, while bands of lower 
frequency are observed between 1592 and 1598 cm-1. Coordination of the 
azomethine nitrogen to the metal is supported by a shift of the existing imine 
band of the ligand towards lower energy.21,22 The new band that forms in the 
region of 1600 cm-1 is as a result of deprotonation of the hydrazinic nitrogens 










Figure 3.3: Infrared spectrum of complex 18 
 
Elemental Analysis and Mass Spectrometry  
Elemental analysis of these compounds was found to be consistent with the 
expected values. ESI mass spectrometry was also conducted on these 
complexes and the results support the structure and composition of these 
complexes. The mass spectrum of 22 displayed a peak of 50% intensity 
corresponding to the protonated form of the complex (m/z 546, [M+H]+). 
Compounds 18-20 display base peaks in their spectra corresponding to their 
respective molecular ions at m/z 457, 487 and 513. The spectra of 21 and 23-
25 display base peaks corresponding to the protonated form of these 
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Single Crystal X-Ray Diffraction Studies   
To further confirm the structure of these complexes, crystals suitable for X-ray 
structure determination were obtained for complex 20. Crystals were grown 
from dimethylsulfoxide (DMSO) at room temperature. Table 3.3 lists selected 
bond parameters. The molecular structure depicts coordination of the 3-tert-
butyl salicylaldimine monothiosemicarbazone ligand in a tridentate manner to 
the palladium centre via the phenolic oxygen, imine nitrogen and sulfur atom 
in a slightly distorted square-planar geometry. The structure confirms that the 
fourth coordination site is occupied by a PTA ligand trans to the imine nitrogen 
(Figure 3.4). 
 
Table 3.3  
Selected bond lengths (Å) and angles (º) for complex 20 
Pd(1A)–O(1A) 2.028(2) O(1A)–Pd(1A)–N(1A) 93.40(9) 
Pd(1A)–N(1A) 2.012(3) N(1A)–Pd(1A)–S(1A) 84.45(8) 
Pd(1A)–S(1A) 2.2389(9) O(1A)–Pd(1A)–P(1A) 91.85(7) 
Pd(1A)–P(1A) 2.2461(10) S(1A)–Pd(1A)–P(1A) 90.19(3) 
N(1A)–C(2A) 1.293(4) O(1A)–Pd(1A)–S(1A) 177.08(7) 
N(2A)–C(1A) 1.313(4) N(1A)–Pd(1A)–P(1A) 173.71(8) 
 
The structure shows the formation of a six- and a five-membered chelate ring 
upon coordination. The structure displays O(1A)–Pd(1A)–N(1A) and  
N(1A)–Pd(1A)– S(1A) bond angles of 93.40(9) and 84.45(8)º, respectively.  
O(1A)–Pd(1A)–P(1A) and S(1A)–Pd(1A)–P(1A) bite angles of 91.85(7) and 
90.19(3)º, respectively, can also be seen. These angles indicate a square- 
planar geometry with slight distortion around the Pd centre, as these angles 
deviate slightly from ideal behaviour.  
































Figure 3.4: Molecular structure of complex 20 with the  
hydrogen atoms omitted for clarity 
 
In comparison to similar monomeric and dimeric Pd triphenylphosphine 
thiosemicarbazone complexes, Pd–O, Pd–N, Pd–S and Pd–P bond distances 
appear quite similar.15-17 Thiosemicarbazones can exist in two tautomeric 
forms i.e. the thione or the thiolate form as depicted in Figure 3.5. 
Coordination of this particular thiosemicarbazone occurs via the thiolate form, 
rather than the thione form due to the formation of a second imine bond 
between C(1A) and N(2A). A value of 1.313(4) Å is assigned to this bond, 
further supporting the notion that the C(1A)–N(2A) bond tends towards 
double-bond character upon coordination. Comparison of the C(1A)–N(2A) 
length to the C(1A)–N(3A) bond length, shows that the latter is slightly longer 
(1.349(4) Å) and therefore suggests single-bond character. The C–S bond 
length is also found to be consistent with coordination of sulfur in the thiolate 
form, with a value of 1.754(4) Å. A previous study by Halder et al.,15 based on 
similar monomeric complexes reported C–S values of approximately 1.74 Å. 
In simple systems it would be expected that a single  
C–S bond length would be approximately 1.82 Å and a double bond would 
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Figure 3.5: Possible tautomeric forms displayed by thiosemicarbazones 
 
Examination of the crystal packing arrangement revealed an extensive 
arrangement of hydrogen bonding between each molecule (Figure 3.6). 
Closer inspection of this packing arrangement revealed hydrogen bonding of 
one molecule to two adjacent molecules via the N2 atoms, amino hydrogens 
and a nitrogen atom belonging to the PTA group. The details of this bonding 












Figure 3.6: Two dimensional crystal packing arrangement of  
complex 20 depicting hydrogen bonding 
Table 3.4  
Hydrogen bond parameters for complex 20 
                                                Bond distances / Å                   Bond angle / º 
D–H···A                                        D–H               H···A               D···A                       DHA 
N(3A)–H(3A1)N···N(2B)         0.905(18)          2.162(19)          3.066(4)                  178(3)  
 
The information obtained herein, in addition to their spectral properties, 















































1) 2 eq. Et3N
2) 2 eq. cis-[M(PTA)2Cl2] EtOH / reflux
6-9
26-33
rationalisation of the mode of coordination based on the various bond 
parameters obtained for complex 20.  
 
3.3. Pd and Pt salicylaldiminato PTA dithiosemicarbazones 
3.3.1.   Synthetic approach and physical properties 
The dinuclear salicylaldiminato complexes were synthesised using the same 
procedure as for the mononuclear derivatives, however, a 1:2, ligand:metal 
ratio was used in order to obtain the required dinuclear analogues (Scheme 














26: R = H, M = Pd 30: R = H, M = Pt 
27: R = 3-OMe, M = Pd 31: R = 3-OMe, M = Pt 
28: R = 3-tBu; M = Pd 32: R = 3-tBu; M = Pt 
29: R = 5-Cl, M = Pd  33: R = 5-Cl, M = Pt 
 
Scheme 3.2: Synthesis of salicylaldiminato dithiosemicarbazone 
Pd and Pt complexes 
 
In the case of compound 28, complexation was carried out at room 
temperature for 72 hours. When comparing the reactivity of the two metal 
precursors, it is observed that complexation of the ligands with the Pt(II) 



















(26-29) and Pt(II) (30-33) thiosemicarbazone complexes were isolated as 
yellow solids in good yields.  
 
3.3.2.   Characterisation 
1H Nuclear Magnetic Resonance Spectroscopy  
Similar trends are observed in the proton NMR spectra for the dinuclear 
complexes (Figure 3.7) in comparison to their mononuclear analogues. NMR 
spectral data could not be obtained for 32, due to its insoluble nature in most 
deuterated solvents. Complexation of the dithiosemicarbazones is supported 
by the absence of the hydrazinic and phenolic proton signals in each 
spectrum. The appearance of signals for the protons of the PTA supported the 


















Figure 3.7: 1H NMR spectrum of complex 26 
 
Splitting of the imine signal into a doublet is also observed due to coupling to 
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observed in all cases when compared to the spectra of the free ligands. Table 
3.5 depicts the imine proton resonances and their corresponding coupling 
constants. In addition to this, a singlet in the region of 3.50 ppm is observed 
for the CH2 protons of the ethylene bridge in each case. From the data it can 
be concluded that the metal coordinates to each half of the free ligand in a 
tridentate manner.    
 
Table 3.5:  










26 Pd H  8.31 13.15 
27 Pd 3-OMe  8.29 13.17 
28 Pd 3-tBu  8.33 13.47 
29 Pd 5-Cl  8.31 12.95 
30 Pt H  8.67 11.19 
31 Pt 3-OMe  8.65 11.18 
32a Pt 3-tBu  - - 
33 Pt 5-Cl  8.64 10.99 
 a Insoluble in common deuterated solvents  
 
13C{1H} Nuclear Magnetic Resonance Spectroscopy 
All the complexes, with exception of 20, 24 and 25 due to their poor solubility 
to record measurable spectra, were characterised using 13C{1H} NMR 
spectroscopy. The data obtained for the remainder of the complexes was 
consistent with the data of the mononuclear compounds. Noticeable shifts of 
the thiolate carbon signals support complexation of the ligands (178.00 ppm in 
the free ligands vs 172.00 ppm in the complexes) as seen with complexes  
18-25.   
 
31P{1H} Nuclear Magnetic Resonance Spectroscopy  
As seen with the mononuclear complexes, the dinuclear compounds also 
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mononuclear counterparts (-40.00 ppm (Pd) and -60.00 ppm (Pt)). This 
attests to the purity of these compounds and supports coordination of the 
metal precursors to the dithiosemicarbazones in a similar manner to the 
monothiosemicarbazones. Similar Pt-P coupling constants (~3300.00 Hz) are 
also observed for the dinuclear Pt(II) complexes as compared to their 
mononuclear analogues. Table 3.6 displays selected 13C{1H} and 31P{1H} 
NMR shifts for these complexes. 
 
Table 3.6  









-C-S          -C=N- 
31P{1H} NMR (ppm) 
[1JPt-P  value 
(Hz)] 
26 Pd H  170.83 149.08 -40.55 
27 Pd 3-OMe  170.15 148.07 -39.22 
28a Pd 3-tBu  - - -40.28 
29 Pd 5-Cl  170.88 147.12 -39.92 
30 Pt H  172.45 147.46 -61.47  [3329.69] 
31 Pt 3-OMe  164.80 144.17 -60.18  [3321.44] 
32b Pt 3-tBu  - - - 
33a Pt 5-Cl  - - -61.60  [3343.30] 
a Insufficient solubility to record a measurable 13C NMR spectrum 
b Insoluble in common deuterated solvents  
 
Infrared Spectroscopy  
Since two absorption bands were observed in the infrared spectrum of each 
mononuclear compound, it was assumed that this would hold true for the 
dinuclear compounds. However, only compounds 30, 31 and 33 displayed two 
bands for each imine stretching frequency in their respective spectra. This 
may be due to an overlap of the various absorption bands and therefore both 
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Elemental Analysis and Mass Spectrometry  
Most of the microanalysis data obtained was consistent with the expected 
values. In some cases calculation of the expected values was carried out 
using solvent inclusion and agreed with the data obtained. Solvated water 
molecules were found to be present in samples 26, 27, 30 and 33. Despite 
extensive drying, virtually no improvement was observed. These samples 
were also submitted for ESI mass spectrometry, with the exception of 32 due 
to its insoluble nature. The results (Table 3.7) obtained for ESI-MS further 
support their integrity.  
 
Table 3.7 
ESI mass spectrometry data for dithiosemicarbazone complexes (26-31 and 33) 
Compound  
 
M R m/z (intensity, %) Assignment 





27 Pd 3-OMe 1001 (100) [M+H]+ 





29 Pd 5-Cl 1009 (5)  [M+H]+ 
30 Pt H 1117 (100)  [M]+ 
31 Pt 3-OMe 1177 (100)  [M]+ 






3.4. Pd and Pt salicylaldiminato PTA trithiosemicarbazones 
3.4.1. Synthetic approach and physical properties 
The trithiosemicarbazones mentioned in Section 2.4, were reacted in a similar 
manner to the mono- and dinuclear derivatives with cis-[Pd(PTA)2Cl2]
 (16) and 




















































1) 3 eq. Et3N








       reflux
11-14
34-41
precursors in the presence of triethylamine for 6-48 hours (Scheme 3.3) 
afforded the proposed Pd(II) and Pt(II) salicylaldiminato trithiosemicarbazone 























34: R = H, M = Pd  38: R = H, M = Pt 
35: R = 3-OMe, M = Pd  39: R = 3-OMe, M = Pt 
36: R = 3-tBu; M = Pd  40: R = 3-tBu; M = Pt 
37: R = 5-Cl, M = Pd   41: R = 5-Cl, M = Pt 
 
Scheme 3.3: Synthesis of salicylaldiminato trithiosemicarbazone complexes 
 
Most of these reactions proceeded readily when refluxing in ethanol and 
methanol giving rise to the desired products. In the case of complex 36, NMR 
data indicated unreacted cis-[Pd(PTA)2Cl2]
 (16) despite different synthetic 
attempts and purification methods. Complexes 39 and 41 were prepared in a 
similar manner to the other compounds of this series, however 50% v/v 
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Complexes 36 and 40 were synthesised by stirring the reactants at room 
temperature. Unlike the mono- and dinuclear derivatives some of these 




1H Nuclear Magnetic Resonance Spectroscopy  
Due to the similarities between the Pd(II) and Pt(II) complexes, their 
spectroscopic properties are discussed collectively (Table 3.8). Analyses 
suggest coordination of each thiosemicarbazone moiety in a dianionic manner 
to each metal centre. This is supported by the absence of signals accounting 
for the phenolic and hydrazinic protons in the spectrum of each of these 
complexes. This suggests coordination of the trithiosemicarbazone in the 
thiolate form as observed for the mono- and dinuclear derivatives. Figure 3.8 
shows the 1H NMR spectrum of one of these compounds.  
 
Table 3.8 










34 Pd H  8.31 12.99 
35 Pd 3-OMe  8.33 13.18 
36 Pd 3-tBu  8.26 13.44 
37 Pd 5-Cl  8.19 12.92 
38 Pt H  8.57 11.20 
39 Pt 3-OMe  8.51 11.22 
40 Pt 3-tBu  8.58 11.35 
41 Pt 5-Cl  8.53 11.04 
 
Similar to the mono- and dinuclear analogues, signals corresponding to the 
aliphatic protons of the PTA ligand appear in the region of 4.50 ppm. In most 
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PTA with the exception of 39, where the N-CH2-N protons are equivalent and 












Figure 3.8: 1H NMR spectrum of 3-methoxysalicylaldiminato  
trithiosemicarbazone Pt Complex (39) 
 
In both the Pd(II) and Pt(II) complexes, the signal for the imine proton appears 
as a doublet due to coordination of the metal-phosphine moiety to the 
azomethine nitrogen resulting in 4JP-H coupling of the spin-active 
31P nucleus 
and that of the azomethine proton. The coupling constants obtained for the Pd 
complexes range between 12.92 and 13.44 Hz, while the Pt complexes 
exhibit J values between 11.04 and 11.35 Hz. When comparing the shifts of 
the complexes and the free ligands there are some significant differences. In 
the case of the Pd(II) complexes a shift of the imine signal upfield (ca. 8.20 
ppm) is observed in comparison to the free trithiosemicarbazones (ca. 8.40 
ppm). In contrast the Pt(II) complexes display shifts downfield (ca. 8.60 ppm) 
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13C{1H} Nuclear Magnetic Resonance Spectroscopy 
Overall the signals accounting for the phenolic carbon atoms appear to shift 
downfield for both the Pd and Pt systems upon coordination. The same 
phenomenon is also observed for the azomethine carbon signals. Shifts from 
approximately 140.00 ppm to 150.00 ppm are observed. In contrast, signals 
corresponding to the thiolate carbon of the complexes (170.00 ppm) are found 
more upfield in comparison to the free ligands (177.00 ppm). This is mainly 
attributed to an increased electron-density at the site of coordination due to π 
back-bonding at the thiolato sulfur.4 
 
31P{1H} Nuclear Magnetic Resonance Spectroscopy 
31P{1H} NMR spectroscopy was employed in order to further confirm 
complexation of the ligand to the respective metal precursors. As with the 
mono- and dinuclear derivatives, compounds (34-37) display singlets in the 
region of -40.00 ppm, while the corresponding Pt derivatives (38-41) display 
typical resonances at approximately -60.00 ppm. The coupling constants 
observed for the Pt compounds are consistent with 1JPt-P constants of the 
afore-mentioned complexes. Typical 13C{1H} and 31P{1H} NMR resonances 
and coupling constants are observed in Table 3.9. 
 
Infrared Spectroscopy  
Coordination of ligands 11-14 in the thiolate form suggests that a second 
imine bond forms upon deprotonation of the hydrazinic nitrogen. Two 
absorption bands are found in the spectrum of most of the compounds, 
absorption bands of higher frequency are observed between 1621 and 1631 
cm-1, while bands of lower frequency are observed between 1592 and 1599 
cm-1. The former is attributed to the new imine bond upon complexation. The 
latter is attributed to the existing imine bond which shifts to lower frequency 
upon coordination to the metal. The ν(C=S) bands of the ligand appear less 
intense in the complexes and are observed at lower frequencies which 
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metal to sulfur in the thiolate form after deprotonation of the hydrazinic proton 
and appear consistent with similar tridentate TSC systems.21-23 
 
Table 3.9  









   -C-S          -C=N- 
31P{1H} NMR (ppm) 
[1JPt-P  value  
(Hz)] 
34 Pd H  171.15 147.57 -40.55 
35 Pd 3-OMe  170.82 148.16 -36.00 
36 Pd 3-tBu  169.41 149.51 -40.11 
37 Pd 5-Cl  170.69 146.51 -36.32 
38 Pt H  172.32 145.90 -61.49  [3348.80] 
39 Pt 3-OMe  171.51 145.66 -56.90  [3333.81] 
40 Pt 3-tBu  171.31 147.81 -60.76  [3340.49] 
41 Pt 5-Cl  172.36 145.72 -58.19  [3341.09] 
 
Elemental Analysis and Mass Spectrometry  
Although elemental analysis of these compounds was found to be consistent 
with the expected values, in some cases the microanalysis revealed the 
presence of water molecules as seen with the dinuclear compounds. Mass 
spectrometry data also supports the integrity of these complexes. In most 
cases the ESI spectra displayed peaks of the form [M+2H]2+ as the base 
peaks. Peaks of the form [M+H]+ and [M]+ are also observed, although with 
lower intensities. Table 3.10 displays some results obtained from the ESI 





















ESI mass spectrometry data for the trithiosemicarbazone complexes (34-41) 
Compound M R m/z (intensity, %) Assignment 
34 Pd H 1466 (25)  [M+H]+ 















38 Pt H 
1731 (50) 
 [M]+ 
39 Pt 3-OMe 
















Overall, the mono-, di- and trinuclear Pd(II) and Pt(II) complexes exhibit 
similar physical and spectroscopic properties. All complexes were obtained 
using templated synthetic chemical procedures very effectively in moderate to 
good yields. The spectroscopic and analytical data undoubtedly support their 
composition and structure. Although these compounds display a slight 
improvement of solubility in some organic solvents including DMSO in 
comparison to similar triphenylphosphine complexes, little to no improvement 
was observed in water. The thiosemicarbazone complexes that were 
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thiosemicarbazone moiety. The solubility of these compounds did not improve 
substantially despite the use of a water soluble co-ligand. There has also 
been a report of self-aggregation of these thiosemicarbazone systems which 
may contribute to their water-insoluble nature.24 
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Platinum-based drugs have been used clinically in recent years.1 Many of 
these compounds, however, exhibit high toxicity as well as drug resistance 
which limits their clinical applications.2,3 Ruthenium compounds have therefore 
been considered as a viable alternative to classical platinum-containing 
compounds. Many ruthenium compounds are less toxic than platinum based 
drugs and in some cases are found to be selective towards cancer cells.4,5 
Two ruthenium(III) complexes that have successfully completed phase I 
clinical trials, [imiH]trans-[Ru(N-imi)(S-dmso)Cl4] (NAMI-A) (Figure 4.1.i) and 
[indH]trans-[Ru(N-ind)2Cl4] (KP1019) (Figure 4.1.ii), where imi = imidazole and 
ind = indazole, provided the initial breakthrough into this field of research.6-10  



























  i              ii 
 
Figure 4.1: Ru(III) complexes in clinical trials towards the treatment of cancer 
 
Half-sandwich organometallic arene ruthenium(II) complexes have attracted 
considerable interest as potential anticancer agents. Recently complexes of 
the type [Ru(η6-arene)(en)Cl][PF6] (en = ethylenediamine) have exhibited 
promising anticancer activity.11 This part of the study therefore focused on the 
preparation of thiosemicarbazones using arene ruthenium(II) precursors for 
complexation to potentially obtain more soluble and potent complexes for 
biological testing.  The focus of this section is therefore two-fold, i.e. (1) to 
produce more soluble complexes for testing and (2) to employ the use of 
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4.2. Preparation of thiosemicarbazone ligands (42-46) 
4.2.1. Synthetic approach and physical properties 
The chemistry and biological activity of arene ruthenium complexes has been 
investigated extensively in recent years.12 These complexes are usually 
prepared using similar procedures and reactions proceed without major 
complications, provided an appropriate ligand system is introduced. In this 
study thiosemicarbazones derived from benzaldehyde were used. Reaction of 
benzaldehyde monothiosemicarbazone (42) with the arene ruthenium(II) 
precursor revealed that thiosemicarbazones not possessing any heteroatoms 
on the aryl ring provide the best systems for coordination to ruthenium in the 
desired manner, as this would limit the number of coordination sites for the 
metal (see Section 4.3). Recent literature also reports the use of 
anthraldehyde thiosemicarbazones as appropriate scaffolds for coordination 
of thiosemicarbazones to ruthenium arene precursors.13 Arene ruthenium(II) 
p-chloroacetophenone phenylthiosemicarbazone complexes were also 
prepared for the use in the transfer hydrogenation of ketones.14 Based on this 
it was decided to prepare mono-, di- and trithiosemicarbazones derived from a 
simple system such as benzaldehyde for subsequent reaction with arene 
ruthenium precursors. 
 
Benzaldehyde monothiosemicarbazone (42) was prepared similarly to the 
salicylaldimine monothiosemicarbazones mentioned in Section 2.2.  
Thiosemicarbazide, suspended in methanol, was refluxed with benzaldehyde 
resulting in a clear solution. Excess water was added to the solution to 
precipitate a white solid which upon characterisation proved to be the desired 
product. Scheme 4.1 outlines the preparation of 42. 
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Ethane-1,2-benzaldehyde dithiosemicarbazone (43) was prepared in a 68% 
yield by refluxing benzaldehyde and ethane-1,2-dithiosemicarbazide (5) in a 
2:1 mole ratio in methanol (Scheme 4.2). Subsequent reaction of this ligand 
with the p-cymene ruthenium(II) precursor (see Section 4.3), did not give rise 
to the desired dinuclear complex. No proposed structure was discernible from 
the 1H NMR spectrum obtained. It was then decided to alter the ligand system 
slightly in order to investigate the reactivity of these dithiosemicarbazones with 
ruthenium. It was believed that the spacer may perhaps contribute towards 
the outcome of these reactions. It was thought that alteration of the more 
flexible ethane bridge to a rigid, electron-withdrawing benzene moiety may aid 

































Scheme 4.2: Preparation of a non-rigid dithiosemicarbazone (43)  
 
Benzene-1,4-dithiosemicarbazide (44) was prepared by a procedure 
previously reported by Dilworth et al.15 Commercially available phenylene-1,4-
diisothiocyanate is treated with hydrazine hydrate in a mixture of water and 
ethanol resulting in the rigid dithiosemicarbazide.15 Benzene-1,4-
benzaldehyde dithiosemicarbazone (45) was prepared by means of a  
Schiff-base condensation reaction between benzaldehyde and benzene-1,4-
dithiosemicarbazide in MeOH under reflux conditions. The preparation of 


























Scheme 4.3: Preparation of a rigid dithiosemicarbazone (45)  
 
A trithiosemicarbazone derivative was also prepared for complexation with 
ruthenium. The non-rigid trimeric derivative 46 (Figure 4.2), was prepared 
from tris(2-aminoethyl) thiosemicarbazide and benzaldehyde as per the 
trithiosemicarbazone salicylaldimine ligands by refluxing the contents in 
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1H Nuclear Magnetic Resonance Spectroscopy 
The NMR spectra of ligands 42-46 were recorded in DMSO-d6 Signals 
accounting for the azomethine hydrogen atoms are observed between 8.04 
and 8.06 ppm for compounds 42, 43 and 46. This particular signal appears 
more downfield in the case of 45 which is attributed to the presence of the 
electron-withdrawing phenyl spacer. The signal for the hydrazinic proton is 
also observed relatively downfield, at approximately 12.06 ppm, in comparison 
to the rest of the compounds where the signals appear between 11.31 and 
11.45 ppm. The presence of signals for the hydrazinic protons suggests that 
the thiosemicarbazones exist as neutral ligands with the sulfur in the thione 
form. Signals for the aliphatic bridges are observed as a singlet at 3.87 ppm 
for ligand 43 and at 2.70 and 3.45 ppm, respectively, for compound 46. A 
sharp singlet is observed at 7.92 ppm for the protons of the phenyl bridge of 
ligand 45.   
 
 13C{1H} Nuclear Magnetic Resonance Spectroscopy  
The 13C{1H} NMR data obtained for these compounds supports the 1H NMR 
spectral results. Signals for the imine carbon atoms are observed between 
142.47 and 143.30 ppm. The thione carbon signals are seen in the region of 
176.43 and 178.40 ppm. The spectra of these ligands exhibit the appropriate 
number of signals, thus supporting their structure. The detailed 1H NMR and 
31C{1H} NMR spectral data are given in the experimental section. Table 4.1 
gives selected spectral data obtained for these benzaldehyde 


























1H                         13C 
-HC=N-    -NH-       -C=N-     -C=S 
42 8.05 11.31 142.73 178.40 
43 8.06 11.45 142.86 178.01 
45 8.52 12.06 143.30 176.43 
46 8.04 11.38 142.47 177.58 
 
Infrared Spectroscopy  
Due to the limited solubility of these ligands in many organic solvents, solid-
state infrared studies were used to evaluate these compounds. These 
experiments were carried out using KBr pellets. Strong absorption bands 
observed in the region of 1591 and 1634 cm-1 are attributed to the C=N 
stretching frequencies. The presence of these bands supports the structure of 
these compounds. The absorption bands confirm condensation of 
benzaldehyde with the respective thiosemicarbazides. The thione (C=S) 
stretching frequencies occur at approximately 870 cm-1, thus providing further 
evidence that these ligands exist as their thione tautomers.   
 
4.3. Preparation of ( η6-Arene)ruthenium(II) TSC complexes (47-52) 
4.3.1. Synthetic approach and physical properties 
Reaction of the afore-mentioned benzaldehyde thiosemicarbazone ligands 
with two ruthenium arene precursors, i.e. [Ru(η6-p-cymene)(µ-Cl)Cl]2 (47) 16 
and [Ru(η6-C6H5(CH2)3COOH)(µ-Cl)Cl]2 (48),17 was investigated (Scheme 
4.5). All reactions were carried out at ambient temperature in either 
dichloromethane or methanol. The reaction of 42 with [Ru(η6-p-cymene)(µ-
Cl)Cl] in MeOH at room temperature resulted in a red solution which upon 
concentration and addition of diethyl ether resulted in precipitation of the 
cationic complex 49 as a red powder in a yield of 62%. Ligand 42 was also 
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p-cymene derivative, giving rise to a red solid (50). The reaction mixture was 
filtered, washed with diethyl ether and dried in vacuo resulting in a red powder 














Scheme 4.5: Preparation of mononuclear arene-ruthenium(II) complexes (49 and 50) 
 
The dinuclear complexes were obtained using similar chemical procedures as 
outlined above. The compounds obtained from the reactions involving the rigid 
dithiosemicarbazone (45) display a similar mode of coordination to the 
mononuclear compounds. The results obtained from the reaction involving 
ligand 43 were inconclusive. The product of this reaction displayed similar 
physical properties to the mononuclear derivative (reddish powder, similar 
solubility profile). The 1H NMR spectrum suggests the formation of a 
thiosemicarbazone ruthenium complex, however broadened and overlapping 
peaks made identifying the compound difficult. It is believed that perhaps the 
flexibility of the spacer may affect the outcome of the reaction. The flexible 
nature of the spacer may prevent coordination of the metal to each side of the 
ligand only and perhaps additional ruthenium thiosemicarbazone species are 
formed as the non-rigid ligand (43) (Figure 4.3) can orientate in various ways. 
The rigid derivative (45) is not able to orientate as much and thus ruthenium 
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Figure 4.3: Two dithiosemicarbazone systems (43 and 45) 
investigated in this study 
 
Compound 45 was reacted in MeOH with [Ru(η6-p-cymene)(µ-Cl)Cl]2 (47) at 
room temperature (Scheme 4.6). The red-orange solution obtained was 
evaporated, DCM added and diethyl ether utilised to precipitate the product. 
The orange powder (51) was isolated in 59% yield. Ligand 45 was also 
complexed with [Ru(η6-C6H5(CH2)3COOH)(µ-Cl)Cl]2 (48) giving rise to an 
orange powder in a yield of 89% (52).     


































Flexible spacer may prevent formation of the expected dinuclear complex

































Scheme 4.6: Preparation of dinuclear arene ruthenium complexes (51 and 52)  
 
The reaction involving trithiosemicarbazone 46 with the p-cymene dimer gave 
a similar result to the reaction involving the non-rigid dithiosemicarbazone 
ligand (43). The reason why these particular reactions were not successful is 




1H Nuclear Magnetic Resonance Spectroscopy 
The NMR spectra of the ruthenium p-cymene complexes (49 and 51) were run 
in CDCl3-d, while the spectra of the carboxylic acid derivatives (50 and 52) 
were obtained in CD3OD-d4. Figure 4.4 displays a representative 
1H NMR 
spectrum for a carboxylic derived complex (i.e. complex 50). Evaluation of the 
spectra revealed that upon complexation of the respective ligands to the 







































































p-cymene and the carboxylic acid arene ligands. The loss of symmetry is 
evidenced by the appearance of four sets of doublets in the region of 4.60 and 
5.40 ppm accounting for the protons of the p-cymene rings of complexes 49 
and 51. The methyl substituents of the isopropyl group are observed as two 
distinct doublets in the aliphatic region of the spectra which further confirms 
the loss of planarity as the two methyl groups are non-equivalent. These 
methyl protons are observed at 1.07 and 1.13 ppm for complex 49 and at 1.09 
and 1.15 ppm for complex 51. The presence of the hydrazinic protons suggest 
coordination of the ligands in the thione form to the metal. In the case of the 
carboxylic acid derivatives (50 and 52), three sets of triplets and two sets of 
doublets are observed for the arene ring and are found in the region of 5.00–
5.50 ppm. This loss of symmetry may suggest that these complexes have 
similar modes of coordination. The loss of planarity is also consistent with the 
spectroscopic data obtained for similar arene-ruthenium(II) complexes 
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Singlets for the imine protons are observed at 9.05 (49), 8.81 (50), 9.04 (51) 
and 8.90 ppm (52). A downfield shift is observed for these signals of the free 
ligands upon coordination to ruthenium. This suggests coordination of the 
metal to the imine nitrogen atom as the signal becomes more deshielded in 
each case. This is also observed for other arene-ruthenium 
thiosemicarbazone complexes.13 From this data it is believed that the ligands 
coordinate in a neutral manner to the ruthenium metal via the imine nitrogen 
and thione sulfur atoms thus giving rise to stereogenic ruthenium centres.   
 
13C{1H} Nuclear Magnetic Resonance Spectroscopy  
The 13C{1H} NMR spectra of 49 and 51 are very similar. The carbon signals 
attributed to the methyl group of the p-cymene moiety is observed at ca. 18.00 
ppm. The signals for the two carbon atoms of the methyl groups of the 
isopropyl moiety are found at approximately 21.00 and 23.00 ppm, 
respectively. Signals for the thione carbon atoms are found at 177.54 and 
175.97 ppm for 49 and 51, respectively. These signals are found at similar 
chemical shifts for the free ligands with values of 178.40 and 176.43 ppm for 
ligands 42 and 45. The imine signals are found relatively downfield (~161.00 
ppm) in comparison to the free ligands (~140.00 ppm), supporting 
coordination of the imine nitrogen to ruthenium.  
 
Signals for the aliphatic carbon atoms of the arene moiety for complexes 50 
and 52 appear between 25.00 and 33.00 ppm. The carbonyl carbon atom 
signals of the carboxylic acid moiety occur at 174.98 and 170.61 ppm, 
respectively. Signals for the thione carbon atoms appear at similar shifts to the 
p-cymene derivatives with signals observed at 177.82 and 174.77 ppm. The 
imine signals for these complexes are also observed at 162.35 and 164.86 
ppm which is slightly more deshielded than the same signals of the p-cymene 
derivatives. The 13C{1H} NMR spectra of these complexes undoubtedly attests 
to the preparation of these complexes. Chapter 7 gives a detailed account of 
the NMR spectroscopic data of these compounds. Table 4.2 gives selected 















NMR spectroscopic data obtained for arene-Ru(II) TSC complexes 
 
Complex 
                         NMR (ppm) 
             1H                                13C 
   -HC=N-           -C=O       -C=N-         -C=S 
49 9.05 - 161.65 177.54 
50 8.81 174.98 162.35 177.82 
51 9.04 - 161.45 175.97 
52 8.90 170.61 164.86 174.77 
 
 
Infrared Spectroscopy  
It is noteworthy that the absorption patterns for these complexes are similar. 
The imine (C=N) absorption bands for the two p-cymene derivatives appear at 
ca. 1616 cm-1, while these stretching frequencies appear at 1600 cm-1 for 
compounds 50 and 52. Absorption bands for the C=S stretching frequencies 
are found at similar frequencies to that of their corresponding free ligands, 
which suggests that the ligand remains in the thione form when coordinated to 
ruthenium. Bands at approximately 1700 cm-1 are attributed to the C=O 
stretching frequencies of the arene ligands for compounds 50 and 52.        
 
ESI Mass Spectrometry and Elemental Analysis 
The ESI mass spectra of these complexes do not display molecular ion peaks 
for these compounds, however, a base peak corresponding to the fragment of 
the form [M-H-2Cl]+ is observed for 49, while a peak of 85% intensity 
corresponding to the fragment [M-5H-4Cl+2Na]+ is observed for 51. A 
fragment corresponding to [M-H-2HCl]+ is observed for 50, while a base peak 
accounting for [M-2Cl-CO2]
2+ is observed for complex 52. Elemental analysis 
confirmed the composition of these compounds. The data obtained for 49, 50 
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Single Crystal X-Ray Diffraction Studies 
The mode of coordination of one of these compounds was determined using 
single crystal X-ray diffraction. The molecular structure of complex 49 is 
illustrated in Figure 4.5. Crystals suitable for structure determination were 
grown by slow diffusion of diethyl ether into a 5:1 v/v MeOH and DCM 
solution. The compound crystallises in the monoclinic space group C2/c. The 
compound crystallises as its chloride salt along with one molecule of methanol 
(Figure 4.5). This is one of a few examples of a half-sandwich 




Figure 4.5: Molecular structure of (η6-p-cymene)ruthenium(II)  
benzaldehyde TSC complex 49 
 
The molecular structure confirms the coordination of the thiosemicarbazone 
ligand (42) in a neutral manner with the ruthenium metal centre through the  
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nitrogen atoms. The complex adopts the commonly observed piano-stool 
geometry of many half-sandwich arene-ruthenium(II) complexes.13,14,18-21 In 
this case, the p-cymene ring forms the seat of the piano-stool, while the 
bidentate thiosemicarbazone (N, S) and the chlorido ligand form the three legs 
of the stool. Selected bond parameters are quoted in Table 4.3. 
   
Table 4.3 
Selected bond lengths (Å) and angles (º) for complex 49 
Ru(1)-Cl(1)                         2.402(15)                        N(3)-Ru(1)-S(1)                  81.87(12) 
Ru(1)-S(1)                      2.357(15)                       N(3)-Ru(1)-Cl(1)                  83.41(11) 
Ru(1)-C(9)                      2.204(5)                         S(1)-Ru(1)-Cl(1)                  86.50(5) 
Ru(1)-C(10)                    2.165(5) 
Ru(1)-C(11)                        2.242(5) 
Ru(1)-C(12)                    2.263(6) 
Ru(1)-C(13)                        2.190(6) 
Ru(1)-C(14)                        2.175(5) 
 
Internuclear distances of 2.201 between Cl(2) and H1(B) as well as 2.295 Å 
between H(1A) and O(1) of the solvated MeOH molecule is indicative of 
hydrogen bonding. The ruthenium centre adopts a pseudo-tetrahedral 
geometry as the p-cymene ligand essentially occupies one coordination site. 
Bond angles of 81.87(12), 83.41(11) and 86.50(5)º are observed for  
N(3)-Ru(1)-S(1), N(3)-Ru(1)-Cl and S(1)-Ru(1)-Cl(1), respectively. On closer 
examination of the bond lengths, it appears as though the p-cymene ligand is 
asymmetrically coordinated to the metal centre as the Ru-Carene bond lengths 
are variable. This is also observed for a similar anthraldehyde TSC complex.13 
It is believed that the distortion may minimise steric interaction between the p-
cymene ligand and the thiosemicarbazone. An average Ru-Carene bond length 

















The preparation and characterisation of four new cationic organometallic 
arene-ruthenium(II) complexes has been discussed in this section. The 
characterisation of these complexes is in accordance with the proposed 
structures. Based on the molecular structure of 49, it is believed that the 
thiosemicarbazone ligands coordinate in a bidentate manner to form cationic 
complexes.  These complexes are readily soluble in most common organic 
solvents (DCM, CHCl3, MeOH, EtOH, DMSO etc). These compounds 
therefore display improved solubility compared to the palladium and platinum 
salicylaldiminato complexes mentioned in Chapter 3 and are good candidates 
for biological evaluation.    
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Anticancer and Antiparasitic Activity 

















The use of mononuclear thiosemicarbazone platinum group metal complexes 
as potential anticancer agents has been investigated extensively as discussed 
in Chapter 1. Investigation into the biological activity of larger TSC molecules 
is limited in literature. This therefore prompted our investigation into the 
design and synthesis of larger thiosemicarbazone systems for biological 
evaluation. The design of trithiosemicarbazone compounds as potential 
anticancer agents stemmed from the phenomenon that macromolecules are 
able to accumulate more efficiently in tumour cells in comparison to healthy 
cells.1 This phenomenon is referred to as the Enhanced Permeability and 
Retention (EPR) effect.  
 
Tumourous cells display increased vascular permeability due to an increased 
porosity of surrounding blood vessels. This aids in the diffusion of 
macromolecules into the cancerous cells. Once inside the cells, the molecules 
are retained due to poor lymphatic drainage by the tumour cell.1 This 
therefore promotes the use of larger compounds for selective targeting of 
abnormal cells. Although the systems investigated in this study are not 
considered to be macromolecules, it is worthwhile investigating the effect of 
varying size and nuclearity on biological activity. Recently, poly(propylene) 
imine (PPI) dendrimers possessing arene-ruthenium(II) moieties have been 
found to show cytotoxicity which is dependent on the size of the molecule.2 It 
was observed that complexes of higher molecular weight (generation 2) show 
increased efficacy against tumour cell growth than their corresponding 
mononuclear analogues.2 This chapter discusses the results obtained from 
the biological evaluation of selected thiosemicarbazone ligands and 
complexes. These compounds were screened for their anticancer and 
antiparasitic activity against the WHCO1 oesophageal cancer cell-line and the 


















5.2. Anticancer studies 
5.2.1. Anticancer evaluation of salicylaldimine TSC compounds  
Anticancer data was obtained for selected salicylaldimine thiosemicarbazone 
compounds (Figure 5.1) discussed in Chapters 2 and 3. The results obtained 
for these tests are summarised in Table 5.1. The compounds were screened 

















Figure 5.1 : General structures of thiosemicarbazone compounds screened against 
WHCO1 cells (R and M defined in Table 5.1) 
 
Oesophageal cancer is one of the most commonly occurring tumours that 
exist and therefore new chemotherapeutics are constantly required to 
overcome drug resistance.3 Thiosemicarbazones are good candidates as 
potential anticancer agents due to their vast biological applications. In this 
study compounds showing insufficient solubility in aqueous DMSO were 
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expressed in terms of an IC50 value, which is the minimum concentration of 
the compound required to inhibit 50% of cell proliferation. The lower the 
concentration, the more effective the compound is. 
   
Table 5.1 
IC50 values obtained for the in vitro anticancer studies on selected compounds TSC  




1 H mono - 72.00 50.49 - 102.70 
2 3-OMe mono - 68.40 15.43 - 303.10 
3 3-tBu mono - 4.89 3.38 – 7.06 
4 5-Cl mono - 15.34 12.42 - 18.96 
6 H di - 6.81 5.87 – 7.88 
7 3-OMe di - 2.34 1.51 - 3.62 
8 3-tBu di - 1.75 1.32 – 2.32 
9 5-Cl di - 4.43 3.79 - 5.17 
11 H tri - > 200 - 
12 3-OMe tri - 32.98 24.20 – 44.95 
14 5-Cl tri - 4.42 3.65 - 5.34 
18 H mono Pd 1.37 1.10 - 1.70 
19 3-OMe mono Pd 1.04 0.97 - 1.10 
20 3-tBu mono Pd 1.05 0.82 - 1.35 
22 H mono Pt 68.59 20.45 - 230.10 
23 3-OMe mono Pt 17.43 3.796 - 80.06 
24 3-tBu mono Pt 11.79 n/d* 
35 3-OMe tri Pd > 200 - 
39 3-OMe tri Pt > 200 - 
41 5-Cl tri Pt 3.14 1.26 - 7.84 
 *Confidence Iinterval could not be determined 
 
From table 5.1, the results for both the monothiosemicarbazone ligands (1-4) 
and dithiosemicarbazones (6-9) reveal moderate to good cytotoxicity. 



























tertiary butyl moiety (3 and 8) display the best cytotoxicity in each series. In 
addition to this, the dithiosemicarbazone ligands display better activities with 
IC50 values ranging between 1.75 and 6.81 µM. The trithiosemicarbazone 
ligands (11 and 12) display moderate to weak activity, while the 5-chloro 
derivative (14) displays the best activity with an IC50 value of 4.42 µM. It 
seemed that varying the number of thiosemicarbazone moieties from two to 
three does not lead to an appreciable increase in the activity of the 
compound. On the other hand, extension of the monothiosemicarbazone 
systems to dithiosemicarbazone ligands leads to an increase in activity 














Figure 5.2: Graphical representation depicting the activity  
between mono- and dithiosemicarbazone ligands 
 
The results obtained for the mononuclear palladium complexes (18-20) are 
promising as all three compounds exhibit enhanced cytotoxicity with IC50 
values lower than 2 µM. It is noteworthy that these Pd(II) complexes show 
better activities compared to cisplatin which displayed moderate potency  
(IC50 = 13 µM) against the WHCO1 cell-line.
4 Cisplatin was not screened 
during this particular evaluation, but was carried out in a previous study on the 
same cell-line using the same protocol.4 The biological evaluation of similar 




















by a triphenylphosphine group (Figure 5.3), were previously reported and 







R = H, 3-OMe, 3-tBu, 5-Cl 
 
Figure 5.3: Similar triphenylphosphine complexes previously reported 
 
Comparison of the results revealed that the PTA derivatives display enhanced 
activity in comparison to their PPh3 counterparts.
5 This may be attributed to 
enhanced solubility of the PTA complexes in the cultivation medium. Although 
the PTA derivatives are not water-soluble, the presence of the PTA ligand 
may alter the lipophilic nature of these compounds, thus aiding permeability of 
the compound into the cell more effectively.  IC50 values of 6.68 (R = H), 
54.38 (R = 3-tBu) and 2.56 µM (R = 3-OMe) were observed for the 
triphenylphosphine analogues.5  
 
Although the R group appears to play a substantial role on the activity of the 
triphenylphosphine derived complexes, this is not the case with the PTA 
analogues. The R group has a miniscule effect on the activity as the IC50 
values obtained for complexes 18-20 are quite similar and are found in the 
range of 1.00 µM. This implies that the phosphine ligand plays a significant 
role on cytotoxicity in comparison to the substituent on the aryl ring in this 
case. Comparison of the activity of the phosphine complexes to their 
monothiosemicarbazone ligands reveal that the complexes do display 
enhanced cytotoxicity and this has also been observed in literature.6,7 Figure 
5.4 depicts the results obtained for the monothiosemicarbazone ligands 
(mono TSC) and their corresponding Pd(II) complexes where the co-ligand (L) 

















































Figure 5.4: Graphical representation of the activity of  
monothiosemicarbazones and their Pd(II) complexes 
 
Comparison of the activity between the Pd(II) and Pt(II) PTA complexes 
shows that the palladium derivatives display much better activity. Previous 
reports have suggested that Pd(II) complexes that possess sulfur-containing 
ligands display better cytotoxic behaviour than complexes containing other 
metals because the Pd(II) complexes are more labile and are able to be 
transported towards DNA more effieciently.8 Another possible reason for low 




The dithiosemicarbazone ligands display the best activity in comparison to the 
other ligand systems. The activity of their metal complexes could not be 
evaluated, however, due to their low solubility in the testing medium. In 
addition to the afore-mentioned compounds, anticancer data was also 
obtained for the trithiosemicarbazone complexes (35, 39 and 41), however 
only complex 41 (where R = 5-Cl and M = Pt) displayed activity. The IC50 
value obtained for this particular complex was 3.14 µM, which is comparable 




















5.2.2. Anticancer evaluation of ( η6-arene)-ruthenium(II) compounds  
The (η6-arene)-ruthenium(II) complexes (49-52) as well as their corresponding 
benzaldehyde ligands (42 and 45) discussed in Chapter 4 were also 
evaluated for their anticancer activity against the WHCO1 oesophageal 
cancer cell-line by means of a colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. This assay is used to monitor the 
inhibition of cell growth. The structures of these compounds are displayed in 
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Figure 5.5 : (η6-arene)-ruthenium(II) complexes evaluated against WHCO1 
 
The results of this particular evaluation are summarised in Table 5.2. With the 
exception of ligand 45 and complex 52, the compounds displayed low 
cytotoxicity in comparison to cisplatin (13 µM) for this particular cell-line. The 
diacid arene complex 52 displayed moderate cytotoxicity against this 
particular cell-line, giving an IC50 value of approximately 8.96 µM. The 
complex does not display any enhanced activity in comparison to its free 
















IC50 values obtained for the in vitro anticancer studies of arene-ruthenium(II) 
complexes and their corresponding TSC ligands 
Compound Type Arene IC 50 (µM) 
95% Confidence 
Interval (CI) 
42 mono - > 200 - 
45 di - 0.21 0.11 - 0.38 
49 mono p-cymene 81.13 69.87 - 94.21 
50 mono acid derivative > 200 - 
51 di p-cymene > 200 - 
52 di acid derivative 8.96 1.26 - 63.78 
 
The cytotoxicity of these particular compounds are low and it may be that 
these compounds do not enter the cells effectively thus preventing 
accumulation of these compounds inside the cells. Low in vitro cytotoxic 
activity has often been observed for potential ruthenium anticancer agents, 
including NAMI-A (a ruthenium(III) drug that has successfully completed 
phase I clinical trials 9). Many ruthenium compounds have been found to 
display enhanced cytotoxicity in vivo despite low in vitro activity. In these 
cases the compounds have increased activity against tumour metastases.10-13  
 
Although, the compounds discussed in Table 5.2 may not display remarkable 
in vitro activity, it is possible that they may exhibit considerable activity when 
evaluated in vivo. Further studies therefore should implemented in order to 
evaluate the potential of these compounds as antiproliferative agents.      
 
5.3. Antiparasitic studies 
In addition to their antitumoural properties, certain thiosemicarbazone 
compounds possess antibacterial, antifungal, antiviral as well as antiparasital 














various parasitic strains including Plasmodium falciparum, (a malarial 
parasite) and Trypanosoma brucei (a parasite that causes sleeping sickness) 
and were found to be effective against these microorganisms.21 Some of 
these thiosemicarbazone compounds have also been classified as cysteine 
protease inhibitors. The proteases are enzymes that degrade polypeptides 
and are able to induce apoptosis of cells. In the search towards more effective 
biological agents, a series of thiosemicarbazone inhibitors of Trypanosoma 
cruzi cysteine protease, cruzain, have been identified.15 The Trichomonas 
vaginalis parasite secretes cysteine proteases that are able to induce 
apoptosis of human vaginal epithelial cells.22 This particular parasite is the 
causative agent of trichomoniasis, a sexually transmitted disease which 
commonly causes infection of the urogenital tract in women.23  
 
Metronidazole (Figure 5.6) is a common drug used to combat trichomoniasis 
in humans. However, 5% of people infected display resistance towards this 
particular drug.24 Thiosemicarbazone compounds may be an effective 











Figure 5.6: 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethanol (metronidazole),   
a drug used to treat trichomoniasis 
 
Selected monomeric compounds (Figure 5.7) were thus screened against 
Trichomonas vaginalis in vitro in order to evaluate these compounds as 
potential cysteine protease inhibitors. Their average percentage growth 
































1-4                                                                         18-21  
 
R = H (1, 18); 3-OMe (2, 19); 3-tBu (3, 20); 5-Cl (4, 21) 
 




Percentage inhibition of monothiosemicarbazones screened against T. vaginalis T1 
 
Since the mononuclear palladium PTA thiosemicarbazones displayed the best 
activity against the WHCO1 oesophageal cancer cell-line in vitro and did not 
present any major solubility issues during the evaluation, it was decided that 
these compounds as well as their corresponding ligands would be screened 
for potential antiparasital activity. Monothiosemicarbazone ligands (1-4) and 
their corresponding palladium PTA complexes (18-21) were screened against 
the T1 strain of T. vaginalis. Comparison of the data obtained for the ligands 
and the complexes, with the exception of complex 18, revealed that the 
Compound R M Average % inhibition 
1 H - 88.89 
2 3-OMe - 60.47 
3 3-tBu - 25.23 
4 5-Cl - 81.47 
18 H Pd 35.44 
19 3-OMe Pd 69.39 
20 3-tBu Pd 97.16 




























complexes display better inhibition against the T1 strain than their 
corresponding ligands. Figure 5.8 gives a graphical representation of the 



















Figure 5.8: Graphical representation comparing the effect 
 of complexation on inhibition of  T. vaginalis T1 
 
As seen with many other TSC compounds, lipophilicity is modified by 
coordination of the metal and therefore an enhancement in activity may be 
observed.25 In some cases the metal may act as a vehicle aiding in activation 
of the ligand once inside the cell. With respect to these compounds, 
complexes 20 (tBu) and 21 (Cl) display the best inhibition against the growth 
of the parasite with more than 90% growth inhibition observed.  
 
Comparison of the free tertiary butyl ligand (3) to its corresponding complex 
(20) reveals a 4-fold increase in inhibition attributed to coordination by 
palladium. In the case of the unsubstituted compounds (1 and 18), the free 
ligand (1) displays better inhibition than its complex (18). There is a minute 
difference in activity between the 5-chloro substituted ligand (4) and its 
complex (21) as these compounds inhibited 81.47 and 95.02% of the growth 




















possessing a chloro substituent on the aryl ring display enhanced efficacy and 
further mechanistic studies should be carried out on these compounds. In the 
case of the complexes it appears that a substituent on the aryl ring improves 
the inhibitory abilities of these compounds as the unsubstituted derivative 
displays the lowest percentage inhibition of the parasite.  
 
5.4. Conclusion 
With regards to the anticancer experiments, the results show that coordination 
of palladium to the monothiosemicarbazone ligands does enhance the 
antiproliferative activity of these compounds, possibly due to increased 
lipophilicity. The results also reveal that the Pd(II) complexes display better 
activity in comparison to the Pt(II) analogues which may be attributed to the 
lability of the metal or the solubility of the complex. Surprisingly, the 
trithiosemicarbazone compounds did not display any remarkable activity in 
comparison to the other molecules. Further investigation of these systems, 
should be carried out in order to develop more effective therapeutics using 
these kinds of systems. Overall, the mononuclear Pd(II) PTA complexes 
displayed the best results with IC50 values in the low micromolar range 
compared to the rest of the screened compounds and should be considered 
as agents with potential antitumour properties. Further in vitro studies 
including mechanistic studies or perhaps in vivo screenings should be 
pursued on these compounds in future.  
 
The arene-ruthenium(II) complexes did not display any remarkable in vitro 
activity. Nevertheless, it may be possible that these compounds may exhibit 
considerable activity when evaluated in vivo. In addition to the anticancer 
activity of these compounds, the monothiosemicarbazones and their Pd(II) 
complexes exhibit moderate to good antiparasitic activity. It appears that 
compounds possessing a chloro substituent on the aryl ring display enhanced 
efficacy and in the case of the complexes, the presence of a substituent on 















Thiosemicarbazones thus exhibit a wide range of biological applications 
based on literature precedence as well as the investigations carried out in this 
study. Based on the data presented in this study, the mono-, di- and 
trithiosemicarbazone compounds possess the potential to be used as 
biological agents, however, further investigation into improving the solubility of 
these compounds needs to be prioritised. While some compounds may not 
have displayed any significant anticancer or antiparasitic activity against the 
cell-line or strain tested, these compounds may be active against other strains 
and also may be used for other biological purposes. These compounds may 
possess antimalarial, antibacterial, antifungal or even antiviral activity. Further 
biological studies should thus be implemented on these compounds in future.        
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6.1. General conclusions 
Thiosemicarbazones possess a wide variety of biological applications and 
therefore the main focus of this study was to prepare a series of 
salicylaldimine thiosemicarbazones and their corresponding palladium and 
platinum complexes in order to evaluate their potential anticancer activity. The 
preparation of salicylaldimine thiosemicarbazones was achieved by simple 
Schiff-base condensation of various substituted salicylaldehydes and 
thiosemicarbazides. These salicylaldimine ligands were complexed using two 
metal precursors of the general formula cis-[M(PTA)2Cl2], where M = Pd and 
Pt. In addition to the salicylaldiminato complexes, a series of  
(η6-arene)ruthenium(II) complexes were also prepared from benzaldehyde 
thiosemicarbazones for biological evaluation.  
 
The ligands and complexes have been characterised by 1H, 13C{1H} and 
31P{1H} (salicylaldiminato complexes) NMR spectroscopy, FT-IR 
spectroscopy, ESI-mass spectrometry and elemental analysis. Molecular 
structures of complexes 20 and 49 were obtained using X-ray diffraction 
analysis to further confirm their mode of coordination. The molecular structure 
of complex 20 revealed that the salicylaldimine ligand coordinates to the 
palladium centre in a tridentate manner through the phenolic oxygen, imine 
nitrogen and thiolate sulfur, resulting in a slightly distorted square-planar 
geometry around the palladium centre. The molecular structure of 49 showed 
that the benzaldehyde thiosemicarbazone coordinates in a bidentate manner 
to the ruthenium centre, giving rise to a cationic complex. The structure also 
shows coordination of the (η6-p-cymene)ruthenium(II) complex in a pseudo-
tetrahedral, piano-stool conformation. 
 
Selected salicylaldiminato and (η6-arene)ruthenium(II) complexes were 
screened for potential anticancer activity against WHCO1 cancer cells. The 
mononuclear Pd(II) salicylaldimine complexes exhibit good activity in 
comparison to the rest of the complexes screened against this particular cell-
line. The rest of the screened compounds, including the  














concentration tested. The low activity of the palladium and platinum 
complexes can be attributed to low solubility of some of these compounds in 
the testing medium. Although the ruthenium complexes do not exhibit any 
remarkable in vitro activity, they may exhibit activity when evaluated in vivo.   
 
In addition to the anticancer evaluation, the mononuclear Pd(II) complexes 
and their parent ligands, were screened in vitro for potential antiparasitic 
activity against the T1 strain of T. vaginalis. Some of the complexes and the 
monothiosemicarbazone ligands possessed moderate to good activity against 
this strain. In particular, the complexes that possessed the 3-tBu and 5-Cl 
substituents displayed the best activity, with more than 90% inhibition 
observed.   
 
6.2. Future aspects 
Thiosemicarbazone compounds are prepared using efficient methods in good 
yields and many of these compounds (mono-, di- and trithiosemicarbazones) 
exhibit promising biological activity. Water-solubility plays a significant role in 
determination of the biological potential of these compounds. If compounds do 
not possess sufficient solubility in the cultivation medium, the compounds may 
not be evaluated for biological activity. Improving the water-solubility of these 
compounds therefore needs to be prioritised in order to test potential 
therapeutic agents.     
 
Further mechanistic in vitro studies should be pursued on the compounds that 
presented good activity. These compounds should be evaluated in order to 
ascertain whether they do indeed act by inhibition of the enzyme 
ribonucleotide reductase (RNR). Particularly, it would be interesting to 
determine whether the di- and trimeric compounds undergo similar cellular 
mechanisms to that of the monomeric analogues. Cellular uptake studies 
should also be implemented in order to investigate the effectiveness of the 
active compounds. In the case of the compounds that do not display any 
remarkable in vitro activity, in vivo studies may be useful to study their 



































Thiosemicarbazide, hydrazine hydrate, sodium chloroacetate,  
1,5-cyclooctadiene, salicylaldehyde, 3-tert-butyl-salicylaldehyde,  
5-chloro-salicylaldehyde, 3-methoxy-salicylaldehyde, 1,3,5-triaza-5-
phosphaadamantane, ethylenediamine, 1,4-phenylene diisothiocyanate and 
tris(2-aminoethyl)amine were purchased from Sigma-Aldrich. Triethylamine 
was purchased from Fluka. Palladium dichloride, potassium 
tetrachloroplatinate and ruthenium trichloride trihydrate was received as a 
donation from Anglo Platinum. Solvents were purchased from Kimix and 
Merck. All reagents and solvents were used as received. Ethane-1,2-
dithiosemicarbazide (5) and benzene-1,4-dithiosemicarbazide (44) were 
prepared according to literature methods.1 Cis-[Pd(COD)Cl2] (15),2  
cis-[Pd(PTA)2Cl2] (16),3 cis-[Pt(PTA)2Cl2] (17),4 [Ru(η6-p-cymene)(µ-Cl)Cl]2 




Nuclear magnetic resonance (NMR) spectra were recorded using a Varian 
Mercury 300 spectrometer (1H at 300.077 MHz, 13C at 75.454 MHz, 31P at 
121.472 MHz), a Varian Unity 400 spectrometer (1H at 399.953 MHz, 13C at 
100.577 MHz, 31P at 161.903 MHz) or a Bruker 400 FT spectrometer (1H at 
400.200 MHz, 13C at 100.600 MHz, 31P at 162.000 MHz). Coupling constants 
are recorded in Hz. Si(CH3)4 (0.00 ppm) was used to calibrate the 
1H and 
13C{1H} chemical shifts. The 31P{1H} spectra were measured using H3PO4 as 
the internal standard. The Samples were submitted in dimethylsulfoxide-d6 
unless otherwise stated. Some 
1H NMR assignments were made using 2D 
Correlation spectroscopy (COSY). 13C{1H} NMR assignments were made with 
the aid of 2D Heteronuclear Single Quantum Coherence (HSQC) 
spectroscopy. 
 
Infrared (IR) spectra were determined using a Perkin Elmer Spectrum One 
FT-IR spectrometer and was carried out in the solid state using KBr pellets 














performed using a Thermo Flash 1112 Series CHNS-O Analyser. ESI-mass 
spectrometry was used to further characterise new compounds and 
determinations were carried out using a Waters API Quattro instrument in 
either the positive or negative mode. Melting points are corrected and were 
determined on a Reichert Thermovar hot stage microscope.  
 
7.3. Synthesis of salicylaldimine TSC ligands 
7.3.1. Synthesis of monothiosemicarbazone salicylaldimine ligands 
 





















Thiosemicarbazide (0.514 g, 5.64 mmol) and salicylaldehyde (0.6 cm3, 5.64 
mmol) were refluxed in ethanol (30 cm3) for 6 hours. The precipitate was 
filtered using a Büchner funnel and the product washed with ethanol. The 
product was isolated as a white powder (0.741 g, 68%). 1H NMR (399.953 
MHz, DMSO–d6): (δ, ppm) 6.86 (2H, m, He, Hg); 7.24 (1H, t, 3JH-H = 7.58,  
Hf); 7.92 (2H, m, Hd, NH2); 8.08 (1H, s, NH2); 8.40 (1H, s, Hb); 9.84 (1H, s, 
OH); 11.36 (1H, s, NH). 13C{1H} NMR (75.454 MHz,  
DMSO–d6): (δ, ppm) 115.95 (Cg); 119.10 (Ce); 120.14 (Cc); 126.78 (Cd); 
130.86 (Cf); 140.02 (Cb); 156.25 (Ch); 177.76 (Ca). FT-IR (KBr): (νmax, cm-1) 
830 (C=S); 1615 (C=N). Elemental analysis calculated for C8H9N3SO: C, 
49.21; H, 4.65; N, 21.53; S, 16.42%. Found: C, 49.74; H, 4.84; N, 21.01; S, 






































Thiosemicarbazide (0.194 g, 2.13 mmol) and 3-methoxy-salicylaldehyde 
(0.323 g, 2.12 mmol) were refluxed in ethanol (30 cm3) for approximately 6 
hours. The precipitate was filtered using a Büchner funnel and the product 
washed with ethanol. The product was isolated as a white powder (0.409 g, 
86%). 1H NMR (399.953 MHz, DMSO–d6): (δ, ppm) 3.32 (3H, s, Hi); 6.78 (1H, 
t, 3JH-H = 7.91, He); 6.97 (1H, dd, 
4JH-H = 1.45, 
3JH-H = 8.02, Hf); 7.48 (1H, dd, 
4JH-H = 1.25, 
3JH-H = 7.96, Hd); 7.88 (2H, s, NH2); 8.42 (1H, s, Hb); 9.16 (1H, s, 
OH); 11.29 (1H, s, NH). 13C{1H} NMR (75.454 MHz,  
DMSO–d6): (δ, ppm) 55.83 (Ci); 112.93 (Cf); 118.23 (Cd); 118.84 (Ce); 120.61 
(Cc); 139.76 (Cb); 145.92 (Cg); 147.83 (Ch); 177.78 (Ca). FT-IR (KBr):  
(νmax, cm-1) 822 (C=S); 1622 (C=N). Elemental analysis calculated for 
C9H11N3SO2: C, 47.98; H, 4.92; N, 18.66; S, 14.23%. Found: C, 47.74; H, 




















































Thiosemicarbazide (0.335 g, 3.68 mmol) and 3-tert-butyl-salicylaldehyde  
(0.63 cm3, 3.68 mmol) were refluxed in ethanol (30 cm3) for 6 hours. The 
precipitate was filtered using a Büchner funnel and the product washed with 
ethanol. The product was isolated as a white crystalline powder (0.671 g, 
73%). 1H NMR (300.077 MHz, DMSO–d6): (δ, ppm) 1.38 (9H, s, Hj); 6.85 (1H, 
t , 3JH-H = 7.71, He); 7.28 (2H, m, Hd, Hf); 7.94 (2H, s, NH2); 8.26 (1H, s, Hb); 
9.95 (1H, s, OH); 11.25 (1H, s, NH). 13C{1H} NMR (75.454 MHz,  
DMSO–d6): (δ, ppm) 29.19 (Ci); 34.29 (Cj); 118.41 (Cc); 119.07 (Ce);  
128.25 (Cd); 129.27 (Cf); 136.59 (Cg); 147.01 (Cb); 155.32 (Ch); 177.94 (Ca). 
FT-IR (KBr): (νmax, cm-1) 827 (C=S); 1614 (C=N). Elemental analysis 
calculated for C12H17N3SO: C, 57.34; H, 6.82; N, 16.72; S, 12.75%. Found: C, 











































Thiosemicarbazide (0.848 g, 9.30 mmol) and 5-chloro-salicylaldehyde  
(1.459 g, 9.32 mmol) were refluxed in ethanol (30 cm3) for 6 hours. The 
precipitate was filtered using a Büchner funnel and the product washed with 
ethanol. The product was isolated as an amorphous white solid (1.399 g, 
66%). 1H NMR (399.953 MHz, DMSO–d6): (δ, ppm) 6.85 (1H, d,  
3JH-H = 8.74, Hg); 7.17 (1H, dd, 
4JH-H = 2.75, 
3JH-H = 8.71, Hf); 8.01 (3H, m, Hd, 
NH2); 8.30 (1H, s, Hb); 10.03 (1H, s, OH); 11.30 (1H, s, NH). 
13C{1H} NMR 
(75.454 MHz, DMSO–d6): (δ, ppm) 117.59 (Cg); 122.20 (Cc); 123.29 (Cd); 
125.38 (Ce); 130.15 (Cf); 137.60 (Cb); 154.98 (Ch); 177.99 (Ca). FT-IR (KBr): 
(νmax, cm-1) 829 (C=S); 1657 (C=N). Elemental analysis calculated for 
C8H8N3SOCl: C, 41.83; H, 3.51; N, 18.30; S, 13.96%. Found: C, 41.84; H, 

























7.3.2. Synthesis of dithiosemicarbazone salicylaldimine ligands 
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Ethane–1,2–dithiosemicarbazide (0.207 g, 0.99 mmol) and salicylaldehyde 
(0.21 cm3, 1.99 mmol) were reacted in DMF (20 cm3) at 120 °C for 5 hours. 
The product was obtained by precipitation with water. The precipitate was 
filtered on a Büchner funnel, washed with water and dried in the oven at  
110 °C to remove water. The product was isolated as  a light yellow powder 
(0.363 g, 88%). 1H NMR (399.953 MHz, DMSO–d6): (δ, ppm) 3.83 (4H, s, Ha); 
6.77 (2H, t, 3JH-H = 7.72, Hf); 6.85 (2H, d, 
3JH-H = 8.17, Hh); 7.19 (2H, t, 
3JH-H = 
7.53,  Hg); 7.96 (2H, d, 
3JH-H = 7.73, He); 8.39 (2H, s, Hc); 8.57 (2H, s, CaNH); 
9.86 (2H, s, OH); 11.47 (2H, s, -CbNHN-). 
13C{1H} NMR (75.454 MHz,  
DMSO–d6): (δ, ppm) 43.32 (Ca); 115.85 (Ch); 118. 99 (Cf); 120.22 (Cd); 126.61 
(Ce); 130.78 (Cg); 139.64 (Cc); 156.22 (Ci); 177.23 (Cb). FT-IR (KBr):  
(νmax, cm-1) 803 (C=S); 1618 (C=N). Elemental analysis  calculated for 
C18H20N6S2O2: C, 51.90; H, 4.84; N, 20.17; S, 15.40%. Found: C, 51.18; H, 
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Ethane–1,2–dithiosemicarbazide (0.204 g, 0.97 mmol) and 3-methoxy- 
salicylaldehyde (0.308 g, 2.02 mmol) were reacted in DMF (20 cm3) at 120 °C 
for 5 hours. The product was obtained by precipitation with water. The 
precipitate was filtered on a Büchner funnel, washed with water and dried in 
the oven at 110 °C. The product was isolated as a p ale yellow powder  
(0.452 g, 98%). 1H NMR (399.953 MHz, DMSO–d6): (δ, ppm) 3.80 (6H, s, Hj); 
3.83 (4H, s, Ha); 6.73 (2H, t, 
3JH-H = 7.98, Hf); 6.94 (2H, d,  
3JH-H = 7.03, Hg); 7.58 (2H, d, 
3JH-H = 7.86, He); 8.41 (2H, s, Hc); 8.56 (2H, s, 
CaNH); 9.12 (2H, s, OH); 11.50 (2H, s, -CbNHN-). 
13C{1H} NMR (75.454 MHz, 
DMSO–d6): (δ, ppm) 43.32 (Ca); 55.79 (Cj); 112.84 (Cg); 118.14 (Ce); 118.74 
(Cf); 120.68 (Cd); 139.44 (Cc); 145.80 (Ch); 147.78 (Ci); 177.23 (Cb). FT-IR 
(KBr): (νmax, cm-1) 813 (C=S); 1671 (C=N). Elemental analysis  calculated for 
C20H24N6S2O4: C, 50.40; H, 5.08; N, 17.63; S, 13.46%. Found: C, 49.79; H, 
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Ethane–1,2–dithiosemicarbazide  (0.223 g, 1.07 mmol) and 3-tert-butyl- 
salicylaldehyde (0.36 cm3, 2.15 mmol) were reacted in DMF (20 cm3) at  
120 °C for 5 hours. The product was obtained by pre cipitation with water. The 
precipitate was filtered on a Büchner funnel, washed with water and dried in 
the oven at 110 °C. The product was isolated as a p ale yellow powder  
(0.568 g, 82%). 1H NMR (399.953 MHz, DMSO–d6): (δ, ppm) 1.39 (18H, s, 
Hk); 3.84 (4H, s, Ha); 6.84 (2H, t, 
3JH-H = 7.67, Hf); 7.24 (4H, m, He & Hg); 8.29 
(2H, s, Hc); 8.60 (2H, s, -CaNH-); 9.96 (2H, s, OH); 11.41 (2H, s, -CbNHN-). 
13C{1H} NMR (100.577 MHz, DMSO–d6): (δ, ppm) 30.06 (Ck); 35.15 (Cj); 
44.33 (Ca); 119.52 (Cf); 120.02 (Cd); 129.14 (Ce); 129.99 (Cg); 137.49 (Ch); 
147.66 (Cc); 156.00 (Ci); 177.88 (Cb). FT-IR (KBr): (νmax, cm-1) 855 (C=S); 
1598 (C=N). Elemental analysis  calculated for C26H36N6S2O2.H2O: C, 57.11; 
H, 7.00; N, 15.37; S, 11.73%. Found: C, 57.55; H, 6.58; N, 16.44; S, 12.80%.  
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Ethane–1,2–dithiosemicarbazide (0.218 g, 1.04 mmol) and  
5-chloro-salicylaldehyde  (0.330 g, 2.11 mmol) were reacted in DMF (20 cm3) 
at 120 °C for 5 hours. The product was obtained by precipitation with water. 
The precipitate was filtered on a Büchner funnel, washed with water and dried 
in the oven at 110 °C. The product was isolated as a yellow powder (0.507 g, 
90%). 1H NMR (399.953 MHz, DMSO–d6): (δ, ppm) 3.88 (4H, s, Ha); 6.89 (2H, 
d, 3JH-H = 8.76, Hh); 7.23 (2H, dd, 
4JH-H = 2.65, 
3JH-H = 8.75, Hg); 8.05 (2H, s, 
He); 8.36 (2H, s, Hc); 8.74 (2H, s, CaNH); 10.27 (2H, s, OH); 11.56 (2H, s,  
-CbNHN-). 
13C{1H} NMR (100.577 MHz, DMSO–d6):  
(δ, ppm) 44.28 (Ca); 118.39 (Ch); 122.96 (Cd); 124.08 (Ce); 126.02 (Cf); 131.08 
(Cg); 138.34 (Cc); 155.85 (Ci); 178.11 (Cb). FT-IR (KBr): (νmax, cm-1) 826 
(C=S); 1616 (C=N). Elemental analysis calculated for C18H18N6S2O2Cl2: C, 
44.54; H, 3.74; N, 17.32; S, 13.21%. Found: C, 44.31; H, 3.73; N, 16.97; S, 


























7.3.3. Synthesis of salicylaldimine trithiosemicarbazone ligands 
 
Synthesis of tris(2-aminoethyl) thiosemicarbazide (trithiosemicarbazide) 
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Tris(2-aminoethyl)amine (1.87 cm3) was added to a solution of NaOH  
(1.502 g,  0.037 mol) in water (25 cm3). To this solution, CS2 (2.27 cm
3) was 
added and the mixture stirred for 4 hours giving rise to an orange solution. 
Sodium chlororacetate (4.375 g, 0.037 mol) was added to the solution and 
stirred for 16 hours. The solution was then acidified with 2M HCl (12 cm3) to 
form a yellow precipitate. To this mixture, NH2NH2
.H2O (10 cm
3) was added 
and the solution stirred at 90°C for 2 hours. The s olution was then removed 
from the heat and stirred overnight yielding an oily off-white substance. The 
product was dried in the oven at 115 °C and upon co oling a pale yellow solid 
is obtained (1.059 g, 23%). 1H NMR (399.953 MHz, DMSO–d6): (δ, ppm) 2.68 
(6H, m, Ha); 3.56 (6H, m, Hb); 4.43 (6H, s, NH2); 7.87 (3H, s, CbNH); 8.60 (3H, 
s, NH2NH). 
13C{1H} NMR (399.953 MHz, DMSO–d6): (δ, ppm) 41.73 (Cb); 
53.57 (Ca); 181.76 (Cc).  Elemental analysis calculated for C9H24N10S3: C, 
29.34; H, 6.54; N, 38.01; S, 26.09%. Found: C, 30.65; H, 6.10; N, 33.33; S, 
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Trithiosemicarbazide (0.146 g, 0.40 mmol) was added to hot ethanol (30 cm3). 
To this mixture, salicylaldehyde (0.13 cm3) was added and the mixture 
refluxed for 8 hours and stirred for a further 16 hours at room temperature. 
The volume of the yellow solution was reduced and water added to precipitate 
the desired product. The product was then filtered on a Büchner funnel, 
washed with water and isolated as a yellow powder (0.207 g, 77%). 1H NMR 
(300.077 MHz, DMSO–d6): (δ, ppm) 2.85 (6H, m, Ha); 3.72 (6H, m, Hb); 6.85 
(6H, t, 3JH-H = 8.82, Hi & Hg); 7.20 (3H, t, 
3JH-H = 8.82, Hh); 7.84 (3H, dd,  
4JH-H = 1.62, 
3JH-H = 7.79, Hf); 8.33 (3H, m, CbNH); 8.38 (3H, s, Hd); 9.79 (3H, 
s, OH); 11.34 (3H, s, -CcNHN-). 
13C{1H} NMR (100.577 MHz, DMSO–d6): (δ, 
ppm) 42.60 (Cb); 53.42 (Ca); 116.83 (Ci); 120.07 (Cg); 121.09 (Ce); 127.27 
(Cf); 131.77 (Ch); 140.00 (Cd); 157.15 (Cj); 177.64 (Cc). FT-IR (KBr): (νmax, cm-
1) 803 (C=S); 1620 (C=N). Elemental analysis calculated for C30H36N10S3O3: 
C, 52.92; H, 5.33; N, 20.57; S, 14.12%. Found: C, 52.86; H, 5.43; N, 19.72; S, 
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Trithiosemicarbazide (0.060g, 0.16 mmol) was added to hot ethanol (30 cm3). 
To this mixture, 3-methoxy-salicylaldehyde (0.076 g, 0.50 mmol) was added 
and the mixture refluxed for 10 hours and stirred for a further 16 hours at room 
temperature. The solution was concentrated and water added to precipitate 
the desired product. The product was then filtered on a Büchner funnel, 
washed with water and isolated as a yellow amorphous solid (0.078 g, 62%). 
1H NMR (399.953 MHz, DMSO–d6): (δ, ppm) 2.71 (6H, m, Ha); 3.63 (6H, m, 
Hb); 3.71 (9H, s, Hk); 6.70 (3H, t, 
3JH-H = 8.04, Hg); 6.86 (3H, d,  
3JH-H = 7.88, Hh); 7.40 (3H, d, 
3JH-H = 7.82, Hf), 8.26 (3H, s, CbNH); 8.32 (3H, s, 
Hd); 9.04 (3H, s, OH); 11.33 (3H, s, -CcNHN-). 
13C{1H} NMR (75.454 MHz,  
DMSO–d6): (δ, ppm) 41.57 (Cb); 52.50 (Ca); 55.82 (Ck); 112.85 (Ch); 117.86 
(Cf); 118.89 (Cg); 120.73 (Ce); 139.16 (Cd); 145.87 (Ci); 147.85 (Cj); 176.88 
(Cc). FT-IR (KBr): (νmax, cm-1) 883 (C=S); 1605 (C=N). Elemental analysis 
calculated for C33H42N10S3O6: C, 51.41; H, 5.49; N, 18.17; S, 12.47%. Found: 
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Trithiosemicarbazide (0.269g, 0.729 mmol) was added to hot ethanol  
(30 cm3). To this mixture, 3-tert-butyl-salicylaldehyde (0.36 cm3) was added 
and the mixture refluxed for 8 hours and stirred overnight at room 
temperature. The solvent was removed completely giving rise to a yellow oil. 
The oil was dissolved in DCM and the product washed with water in a 
separating funnel to remove any unreacted aldehyde. The DCM was 
completely removed giving rise to a dark yellow oil (0.521 g, 84%). 1H NMR 
(399.953 MHz, DMSO–d6): (δ, ppm) 1.36 (27H, m, Hl); 2.86 (6H, m, Ha); 3.72 
(6H, m, Hb); 6.84 (3H, t, 
3JH-H = 7.65, Hg); 7.24 (6H, m,  
Hh & Hf); 8.25 (3H, s, -CbNH-); 8.27 (3H, s, Hd), 10.14 (3H, s, OH); 11.39 (3H, 
s, -CcNHN-). 
13C{1H} NMR (75.454 MHz, DMSO–d6): (δ, ppm) 25.46 (Ck); 
34.91 (Cl); 42.52 (Cb); 52.83 (Ca); 119.16 (Cg); 119.83 (Ce); 128.90 (Cf); 
129.72 (Ch); 137.24 (Ci); 147.19 (Cd); 155.86 (Cj); 177.28 (Cc) FT-IR (KBr):  
(νmax, cm-1) 854 (C=S); 1646 (C=N). Elemental analysis calculated for 
C42H60N10O3S3: C, 59.40; H, 7.12; N, 16.50; S, 11.32%. Found: C, 54.55; H, 
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Trithiosemicarbazide (0.122 g, 0.33 mmol) was added to hot ethanol (30 cm3). 
To this mixture, 5- chloro-salicylaldehyde (0.155 g, 0.99 mmol) was added 
and the mixture refluxed for 8 hours and stirred overnight at room 
temperature. The solvent was concentrated and water was added to 
precipitate the desired product. The product was then filtered on a Büchner 
funnel, washed with water and isolated as a yellow powder (0.226 g, 87%). 1H 
NMR (399.953 MHz, DMSO–d6): (δ, ppm) 2.87 (6H, m, Ha); 3.75 (6H, m, Hb); 
6.91 (3H, d, 3JH-H = 8.72, Hi); 7.24 (3H, dd, 
4JH-H = 2.66, 
3JH-H = 8.73; Hh); 7.98 
(3H, d, 4JH-H = 2.62, Hf); 8.35 (3H, s, Hd); 8.57 (3H, m, -CbNH-); 10.22 (3H, s, 
OH); 11.50 (3H, s, -CcNHN-). 
13C{1H} NMR (75.454 MHz, DMSO–d6): (δ, 
ppm) 41.58 (Cb); 52.56 (Ca); 117.63 (Ci); 122.20 (Ce); 123.26 (Cf); 124.98 
(Cg); 130.11 (Ch); 137.28 (Cd); 154.98 (Cj); 177.02 (Cc). FT-IR (KBr): (νmax,  
cm-1) 821 (C=S); 1618 (C=N). Elemental analysis calculated for 
C30H33N10S3O3Cl3: C, 45.95; H, 4.24; N, 17.86; S, 12.26%. Found: C, 45.28; 

















7.4. Synthesis of palladium and platinum salicylaldiminato complexes 
7.4.1. Synthesis of monothiosemicarbazone complexes 
7.4.1.1. Monothiosemicarbazone Pd(II) complexes 
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Salicylaldimine monothiosemicarbazone (0.055 g, 0.28 mmol), triethylamine 
(0.03 cm3) and cis-[Pd(PTA)2Cl2] (0.138 g, 0.28 mmol) were refluxed in 
ethanol for 10 hours. The precipitate was filtered using a Büchner funnel and 
the product washed with ethanol and diethyl ether. The product obtained was 
a yellow powder (0.098 g, 77%). 1H NMR (300.077 MHz, DMSO–d6): (δ, ppm) 
4.31 (6H, s, Hi); 4.42 (3H, d, 
2JH-H = 13.07, Hj(Eq)); 4.57 (3H, d,  
2JH-H = 12.98, Hj(Ax)); 6.56 (3H, m, NH2, He); 6.89 (1H, d, 
3JH-H = 8.34, Hg); 7.23 
(1H, t,  3JH-H = 8.58, Hf); 7.37 (1H, dd, 
4JH-H = 1.77, 
3JH-H = 7.93, Hd); 8.21 (1H, 
d, 4JP-H = 13.18, Hb). 
31P{1H} NMR (121.472 MHz, DMSO–d6): (δ, ppm) -40.70 
(1P, s, PTA). 13C{1H} NMR (75.454 MHz, DMSO–d6): (δ, ppm) 49.94 (Ci); 
71.87 (Cj); 114.17 (Cg); 117.83 (Cc), 120.59 (Ce); 132.25 (Cd); 134.00 (Cf); 
147.57 (Cb); 161.70 (Ch); 171.17 (Ca). FT-IR (KBr): (νmax, cm-1) 1595 (C=N), 
1615 (C=N). Elemental analysis calculated for C14H19N6SPOPd: C, 36.81; H, 
4.19; N, 18.40; S, 7.02%. Found: C, 36.77; H, 4.24; N, 17.97; S, 6.87%. 















Synthesis of 3-methoxysalicylaldiminato monothiosemicarbazone palladium(II) 
PTA complex 
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3-Methoxy salicylaldimine monothiosemicarbazone (0.053 g, 0.23 mmol), 
triethylamine (0.03 cm3) and cis-[Pd(PTA)2Cl2] (0.114 g, 0.233 mmol) were 
refluxed in ethanol for 8 hours. The precipitate was filtered using a Büchner 
funnel and the product washed with ethanol followed by diethyl ether. The 
product obtained was a yellow powder (0.092 g, 81%). 1H NMR (300.077 
MHz, DMSO–d6): (δ, ppm) 3.84 (3H, s, Hi); 4.41 (6H, s, Hj); 4.51 (3H, d,  
2JH-H = 13.17, Hk(Eq)); 4.64 (3H, d, 
2JH-H = 12.69, Hk(Ax)); 6.56 (1H, t, 
3JH-H = 
7.79, He); 6.64 (2H, s, NH2); 6.95 (1H, dd, 
4JH-H = 1.53, 
3JH-H = 7.59, Hf); 7.07 
(1H, dd, 4JH-H = 1.50, 
3JH-H = 8.13, Hd); 8.27 (1H, d, 
4JP-H = 13.20, Hb). 
31P{1H} 
NMR (121.472 MHz, DMSO–d6): (δ, ppm) -39.37 (1P, s, PTA). 13C{1H} NMR 
(100.577 MHz, DMSO–d6): (δ, ppm) 50.83 (Cj); 57.00 (Ck); 72.68 (Cj); 114.17 
(Ce); 114.89 (Cf); 118.50 (Cc); 126.79 (Cd); 148.16 (Cb); 151.72 (Cg); 153.74 
(Ch); 172.01 (Ca). FT-IR (KBr): (νmax, cm-1) 1596 (C=N), 1623 (C=N). 
Elemental analysis calculated for C15H21N6SPO2Pd: C, 37.00; H, 4.35; N, 
17.27; S, 6.58%. Found: C, 37.18; H, 4.38; N, 16.14; S, 6.01%. ESI-MS: m/z 


















Synthesis of 3-tert butylsalicylaldiminato monothiosemicarbazone 
palladium(II) PTA complex 
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3-tert Butyl salicylaldimine monothiosemicarbazone (0.050 g, 0.20 mmol), 
triethylamine (0.03 cm3) and cis-[Pd(PTA)2Cl2] (0.096 g, 0.19 mmol) were 
refluxed in ethanol for 8 hours. The precipitate was filtered and the product 
washed with ethanol and ether. The product obtained was a yellow 
amorphous solid (0.080 g, 80%). 1H NMR (300.077 MHz, DMSO–d6):  
(δ, ppm) 1.51 (9H, s, Hj); 4.43 (6H, s, Hk); 4.53 (3H, d, 2JH-H = 13.38, Hl(Eq)); 
4.62 (3H, d, 2JH-H = 12.68, Hl(Ax)); 6.60 (3H, m, NH2, He); 7.32 (2H, d,  
3JH-H = 7.91, Hd, Hf); 8.28 (1H, d, 
4JP-H = 13.48, Hb). 
31P{1H} NMR (121.472 
MHz, DMSO–d6): (δ, ppm) -43.77 (1P, s, PTA). 13C{1H} NMR (100.577 MHz,  
DMSO–d6): (δ, ppm) 30.04 (Ci); 35.88 (Cj); 48.92 (Ck); 72.66 (Cl); 114.46 (Ce); 
118.84 (Cc); 131.67 (Cd); 133.89 (Cf); 139.36 (Cg); 149.51 (Cb); 161.85 (Ch); 
170.95 (Ca). FT-IR (KBr): (νmax, cm-1) 1593 (C=N), 1643 (C=N). Elemental 
analysis calculated for C18H27N6SPOPd: C, 42.15; H, 5.30; N, 16.39; S, 
6.25%. Found: C, 42.24; H, 5.35; N, 17.45; S, 5.65%. ESI-MS: m/z 513 



















Synthesis of 5-chlorosalicylaldiminato monothiosemicarbazone palladium(II) 
PTA complex 
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5-Chlorosalicylaldimine monothiosemicarbazone (0.050 g, 0.22 mmol), 
triethylamine (0.03 cm3) and cis-[Pd(PTA)2Cl2] (0.106 g, 0.22 mmol) were 
refluxed in ethanol for 24 hours. The precipitate obtained was filtered and the 
product washed with ethanol and diethyl ether. The product was obtained as a 
yellow powder (0.097 g, 92%). 1H NMR (300.077 MHz, DMSO–d6): (δ, ppm) 
4.31 (6H, s, Hi); 4.42 (3H, d, 
2JH-H = 13.12, Hj(Eq)); 4.58 (3H, d, 
2JH-H = 12.91, 
Hj(Ax)); 6.75 (2H, s, NH2); 6.97 (1H, d, 
3JH-H = 9.02, Hg); 7.27 (1H, dd,  
4JH-H = 2.84, 
3JH-H = 9.00, Hf); 7.55 (2H, d, 
4JH-H = 2.83, Hd); 8.30 (1H, d,  
4JP-H = 13.00, Hb). 
31P{1H} NMR (121.472 MHz, DMSO–d6): (δ, ppm) -40.06 
(1P, s, PTA). 13C{1H} NMR (75.454 MHz, DMSO–d6): (δ, ppm) 49.94 (Ci); 
71.86 (Cj); 117.03 (Cg); 119.08 (Cc); 122.39 (Ce); 131.65 (Cd); 132.03 (Cf); 
146.51 (Cb); 160.36 (Ch); 171.98 (Ca). FT-IR (KBr): (νmax, cm-1) 1595 (C=N), 
1630 (C=N). Elemental analysis calculated for C14H18N6SOClPdP: C, 34.23; 
H, 3.69; N, 17.11; S, 6.53%. Found: C, 34.37; H, 3.77; N, 17.96; S, 5.92%. 
ESI-MS: m/z 493 (100%, [M+H]+); 571 (10%, [M+DMSO+H]+). M.p. no melting 

















7.4.1.2. Monothiosemicarbazone Pt(II) complexes 
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Salicylaldimine monothiosemicarbazone (0.047 g, 0.24 mmol), triethylamine 
(0.03 cm3) and cis-[Pt(PTA)2Cl2] (0.135 g, 0.23 mmol) were refluxed in ethanol 
for 5 hours and stirred for an additional 16 hours at room temperature. The 
precipitate was filtered using a Büchner funnel and the yellow product washed 
well with ethanol and diethyl ether (0.103 g, 81%). 1H NMR (399.953 MHz, 
DMSO–d6): (δ, ppm) 4.31 (6H, s, Hi); 4.49 (3H, d, 2JH-H = 12.97, Hj(Eq)); 4.59 
(3H, d, 2JH-H = 12.76, Hj(Ax)); 6.69 (1H, t, 
3JH-H = 7.28, He); 6.85 (2H, s, NH2); 
7.04 (1H, d, 3JH-H = 8.44, Hg); 7.37 (1H, t, 
3JH-H = 7.58, Hf); 7.56 (1H, d,  
3JH-H = 7.79, Hd); 8.57 (1H, d, 
4JP-H = 11.21, Hb). 
31P{1H} NMR (161.903 MHz,  
DMSO–d6): (δ, ppm) -61.37 (1P, s, PTA), 1JPt-P = 3344.43. 13C{1H} NMR 
(75.454 MHz, DMSO–d6): (δ, ppm) 49.35 (Ci); 71.96 (Cj); 115.03 (Cg); 118.05 
(Cc), 120.71 (Ce); 132.07 (Cd); 133.69 (Cf); 145.90 (Cb); 159.74 (Ch); 172.56 
(Ca). FT-IR (KBr): (νmax, cm-1) 1598 (C=N), 1653 (C=N). Elemental analysis 
calculated for C14H19N6OSPtP: C, 30.83; H, 3.51; N, 15.41; S, 5.88%. Found: 
C, 30.36; H, 3.44; N, 14.85; S, 5.95%. ESI-MS: m/z 546 (50%, [M+H]+).  
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3-Methoxy salicylaldimine monothiosemicarbazone (0.048 g, 0.21 mmol), 
triethylamine (0.03 cm3) and cis-[Pt(PTA)2Cl2] (0.123 g, 0.21 mmol) were 
refluxed in ethanol for 5 hours and stirred for an additional 16 hours at room 
temperature. The precipitate was filtered using a Büchner funnel and the 
product washed with ethanol and ether. The product obtained was a yellow 
amorphous solid (0.110 g, 90%). 1H NMR (300.077 MHz, DMSO–d6): (δ, ppm) 
3.82 (3H, s, Hi); 4.30 (6H, s, Hj); 4.48 (3H, d, 
2JH-H = 13.49, Hk(Eq)); 4.56 (3H, d, 
2JH-H = 12.76, Hk(Ax)); 6.59 (1H, t, 
3JH-H = 7.80, He); 6.70 (2H, s, NH2); 6.99 (1H, 
d, 3JH-H = 6.44, Hf); 7.13 (1H, d, 
3JH-H = 7.04, Hd); 8.51 (1H, d,  
4JP-H = 11.24, Hb). 
31P{1H} NMR (121.472 MHz, DMSO–d6): (δ, ppm) -56.80 
(1P, s, PTA), 1JPt-P = 3334.90. 
13C{1H} NMR (75.454 MHz, DMSO–d6): (δ, 
ppm) 49.56 (Cj); 56.27 (Ci); 72.05 (Ck); 113.74 (Ce); 114.21 (Cf); 118.00 (Cc); 
125.57 (Cd); 145.66 (Cb); 151.06 (Cg); 172.58 (Ca). FT-IR (KBr): (νmax, cm-1) 
1593 (C=N), 1623 (C=N). Elemental analysis calculated for 
C15H21N6O2SPtP: C, 31.30; H, 3.68; N, 14.61; S, 5.57%. Found: C, 31.53; H, 
3.67; N, 14.50; S, 5.36%. ESI-MS: m/z 576 (100%, [M+H]+). M.p.   
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3-tert Butyl salicylaldimine monothiosemicarbazone (0.058 g, 0.23 mmol), 
triethylamine (0.03 cm3) and cis-[Pt(PTA)2Cl2] (0.127 g, 0.22 mmol) were 
refluxed in ethanol for 5 hours and stirred at room temperature for an 
additional 16 hours. The precipitate was washed with ethanol followed by 
diethyl ether and dried in vacuo. The product obtained was a yellow 
amorphous solid (0.112 g, 85%). 1H NMR (300.077 MHz, DMSO–d6): (δ, ppm) 
1.48 (9H, s, Hj); 4.33 (6H, s, Hk); 4.52 (3H, s, Hl); 6.63 (1H, t,
 3JH-H = 7.59,  He); 
6.69 (2H, s,  NH2); 7.37 (2H, m,  Hd, Hf); 8.56 (1H, d, 
4JP-H = 11.37, Hb). 
31P{1H} NMR (121.472 MHz, DMSO–d6): (δ, ppm) -60.71 (1P, s, PTA), 1JPt-P = 
3341.70. 13C{1H} NMR (100.577 MHz, DMSO–d6): (δ, ppm) 30.13 (Ci); 36.04 
(Cj); 51.46 (Ck); 72.87 (Cl); 115.54 (Ce); 119.24 (Cc); 130.14 (Cd); 133.79 (Cf); 
139.04 (Cg); 147.81 (Cb); 159.40 (Ch); 172.40 (Ca). FT-IR (KBr): (νmax, cm-1) 
1594 (C=N), 1642 (C=N). Elemental analysis calculated for C18H27N6OSPtP: 
C, 35.94; H, 4.52; N, 13.97; S, 5.33%. Found: C, 36.09; H, 4.50; N, 13.53; S, 


















Synthesis of 5-chlorosalicylaldiminato monothiosemicarbazone platinum(II) 
PTA complex 
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5-Chlorosalicylaldimine monothiosemicarbazone (0.058 g, 0.25 mmol), 
triethylamine (0.03 cm3) and cis-[Pt(PTA)2Cl2] (0.148 g, 0.25 mmol) were 
refluxed in ethanol for 5 hours and stirred overnight at room temperature. The 
precipitate was filtered using a Büchner funnel and the product washed with 
ethanol and diethyl ether. The product was dried in vacuo and obtained as a 
bright yellow powder (0.139 g, 94%). 1H NMR (300.077 MHz, DMSO–d6): (δ, 
ppm) 4.28 (6H, s, Hi); 4.47 (3H, d, 
2JH-H = 13.29, Hj(Eq)); 4.56 (3H, d, 
2JH-H = 
12.75, Hj(Ax)); 6.82 (2H, s, NH2); 7.03 (1H, d, 
3JH-H = 9.05, Hg); 7.31 (1H, dd, 
4JH-H = 2.81, 
3JH-H = 9.02, Hf); 7.63 (2H, d, 
4JH-H = 2.80, Hd); 8.55 (1H, d, 
4JP-H 
= 11.11, Hb). 
31P{1H} NMR (121.472 MHz, DMSO–d6): (δ, ppm) -58.07 (1P, s, 
PTA), 1JPt-P = 3338.67. 
13C{1H} NMR (100.577 MHz, DMSO–d6): (δ, ppm) 
50.12 (Ci); 72.74 (Cj); 118.90 (Cg); 120.16 (Cc); 123.49 (Ce); 132.37 (Cd); 
132.69 (Cf); 145.72 (Cb); 159.10 (Ch); 174.11 (Ca). FT-IR (KBr): (νmax, cm-1) 
1592 (C=N), 1630 (C=N). Elemental analysis calculated for 
C14H18N6OClSPtP: C, 28.99; H, 3.13; N, 14.49; S, 5.53%. Found: C, 29.57; H, 
3.32; N, 14.13; S, 5.27%. ESI-MS: m/z 581 (100%, [M+H]+). M.p.  no melting 













































7.4.2. Synthesis of dithiosemicarbazone complexes 
7.4.2.1. Dithiosemicarbazone Pd(II) complexes 
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Salicylaldimine dithiosemicarbazone (0.039 g, 0.093 mmol), triethylamine 
(0.02 cm3) and cis-[Pd(PTA)2Cl2] (0.086 g, 0.17 mmol) were refluxed in 
ethanol for 8 hours. The precipitate was filtered using a Büchner funnel and 
the product washed with ethanol. The product obtained was a yellow powder 
(0.067 g, 82%). 1H NMR (300.077 MHz, DMSO–d6): (δ, ppm) 3.40 (4H, s, Ha); 
4.31 (12H, s, Hj); 4.42 (6H, d, 
2JH-H = 13.19, Hk(Eq)); 4.57 (6H, d, 
2JH-H = 12.85, 
Hk(Ax)); 6.56 (2H, t, 
3JH-H = 7.88, Hf); 6.89 (2H, d, 
3JH-H = 8.15, Hh); 7.07 (2H, s, 
NH); 7.23 (2H, t, 3JH-H = 8.55, Hg); 7.38 (2H, dd, 
4JH-H = 1.75,  
3JH-H = 7.98, He); 8.31 (2H, d, 
4JP-H = 13.15, Hc). 
31P{1H} NMR (121.472 MHz,  
DMSO–d6): (δ, ppm) -40.55 (2P, s, PTA). 13C{1H} NMR (100.577 MHz,  
DMSO–d6): (δ, ppm) 45.86 (Ca); 50.65 (Cj); 72.59 (Ck); 115.12 (Ch); 118.66 
(Cd), 121.42 (Cf); 133.23 (Ce); 134.92 (Cg); 149.08 (Cc); 162.44 (Ci); 170.83 
(Cb). FT-IR (KBr): (νmax, cm-1) 1598 (C=N). Elemental analysis calculated for 
C30H40N12S2P2O2Pd2·2H2O: C, 36.93; H, 4.54; N, 17.23; S, 6.57%. Found: C, 
36.96; H, 4.63; N, 18.30; S, 6.03%. ESI-MS: m/z 247 (30%, [M+2H+2Na]4+); 
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3-Methoxy salicylaldimine dithiosemicarbazone (0.051 g, 0.11 mmol), 
triethylamine (0.02 cm3) and cis-[Pd(PTA)2Cl2] (0.103 g, 0.21 mmol) were 
refluxed in ethanol for 8 hours and stirred overnight at room temperature. The 
precipitate was filtered using a Büchner funnel and the product washed with 
ethanol and ether. The product was dried under vacuum and obtained as a 
yellow-orange powder (0.083 g, 79%). 1H NMR (300.077 MHz,  
DMSO–d6): (δ, ppm) 3.41 (4H, s, Ha); 3.77 (6H, s, Hj); 4.33 (12H, s, Hk); 4.43 
(6H, d, 2JH-H = 13.22, Hl(Eq)); 4.56 (6H, d, 
2JH-H = 12.85, Hl(Ax)); 6.49 (2H, t, 
3JH-H 
= 7.69, Hf); 6.89 (2H, dd, 
4JH-H = 1.60, 
3JH-H = 7.68, Hg); 7.03 (4H, m, NH, He); 
8.29 (2H, d, 4JP-H = 13.17, Hc). 
31P{1H} NMR (121.472 MHz, DMSO–d6): (δ, 
ppm) -39.22 (2P, s, PTA). 13C{1H} NMR (100.577 MHz, DMSO–d6): (δ, ppm) 
45.15 (Ca); 50.10 (Ck); 56.28 (Cj); 71.93 (Cl); 113.42 (Cf); 114.40 (Cg), 117.77 
(Cd); 126.04 (Ce); 148.07 (Cc); 150.95 (Ch); 153.12 (Ci); 170.15 (Cb). FT-IR 
(KBr): (νmax, cm-1) 1598 (C=N). Elemental analysis calculated for 
C32H44N12S2P2O4Pd2·2H2O: C, 37.11; H, 4.67; N, 16.23; S, 6.19%. Found: C, 
37.35; H, 4.72; N, 14.95; S, 5.59%. ESI-MS: m/z 1001 (100%, [M+H]+). M.p. 
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3-tert Butyl salicylaldimine dithiosemicarbazone (0.057 g, 0.11 mmol), 
triethylamine (0.03 cm3) and cis-[Pd(PTA)2Cl2] (0.105 g, 0.21 mmol) were 
stirred  in ethanol for 72 hours at room temperature. The precipitate was 
filtered using a Büchner funnel and the product washed with ethanol and 
diethyl ether. The product obtained was a yellow-orange powder and dried in 
vacuo (0.075 g, 81%) . 1H NMR (300.077 MHz, DMSO–d6): (δ, ppm) 1.46 
(18H, s, Hk); 3.52 (2H, s, Ha); 4.37 (12H, s, Hl); 4.47 (6H, d, 
2JH-H = 13.85, 
Hm(Eq)); 4.55 (6H, d, 
2JH-H = 12.70, Hm(Ax)); 6.54 (2H, t, 
3JH-H = 7.58, Hf); 7.09 
(2H, s, NH); 7.30 (4H, m, He, Hg); 8.33 (2H, d, 
4JP-H = 13.47, Hc). 
31P{1H} NMR 
(121.472 MHz, DMSO–d6): (δ, ppm) -40.28 (2P, s, PTA). FT-IR (KBr): (νmax, 
cm-1) 1594 (C=N). Elemental analysis calculated for C38H56N12S2P2O2Pd2: C, 
43.39; H, 5.37; N, 15.98; S, 6.09%. Found: C, 44.17; H, 5.46; N, 18.08; S, 
5.98%. ESI-MS: m/z 365 (100%, [M+H+2Na]3+); 1052 (10%, [M]+). M.p.  
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5-Chlorosalicylaldimine dithiosemicarbazone (0.045 g, 0.09 mmol), 
triethylamine (0.02 cm3) and cis-[Pd(PTA)2Cl2] (0.090 g, 0.18 mmol) were 
refluxed in ethanol for 48 hours. The mixture was allowed to cool to room 
temperature and the precipitate was filtered using a Büchner funnel. The 
product washed with ethanol, washed with ether and dried in vacuo. The 
product obtained was a yellow powder (0.077 g, 83%). 1H NMR (300.077 
MHz, DMSO–d6): (δ, ppm) 3.42 (4H, s, Ha); 4.30 (12H, s, Hj); 4.42 (6H, d,  
2JH-H = 13.12, Hk(Eq)); 4.57 (6H, d, 
2JH-H = 12.93, Hk(Ax)); 6.90 (2H, d, 
3JH-H = 
9.04, Hh); 7.20 (4H, m, NH, Hg); 7.47 (4H, d, 
3JH-H = 2.83, He); 8.31 (2H, d, 
 4JP-H = 12.95, Hc). 
31P{1H} NMR (121.472 MHz, DMSO–d6): (δ, ppm) -39.92 
(2P, s, PTA). 13C{1H} NMR (75.454 MHz, DMSO–d6): (δ, ppm) 45.02 (Ca); 
49.90 (Cj); 71.82 (Ck); 117.10 (Ch); 119.05 (Cd), 122.38 (Cf); 131.75 (Ce); 
132.00 (Cg); 147.12 (Cc); 160.36 (Ci); 170.88 (Cb). FT-IR (KBr): (νmax, cm-1) 
1595 (C=N). Elemental analysis calculated for C30H38N12S2P2O2Cl2Pd2: C, 
35.73; H, 3.79; N, 16.67; S, 6.36%. Found: C, 34.64; H, 4.01; N, 15.11; S, 

















7.4.2.2. Dithiosemicarbazone Pt(II) complexes 
 
Synthesis of salicylaldiminato dithiosemicarbazone platinum(II) PTA complex 
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Salicylaldimine dithiosemicarbazone (0.070 g, 0.167 mmol), triethylamine 
(0.04 cm3) and cis-[Pt(PTA)2Cl2] (0.191 g, 0.329 mmol) were refluxed in 
ethanol for 5 hours and stirred overnight at room temperature. The precipitate 
was filtered using a Büchner funnel and the product washed with ethanol and 
diethyl ether. The product obtained was a yellow powder (0.141 g, 83%). 1H 
NMR (399.952 MHz, DMSO–d6): (δ, ppm) 3.52 (4H, s, Ha); 4.29 (12H, s, Hj); 
4.48 (6H, d, 2JH-H = 13.06, Hk(Eq)); 4.57 (6H, d, 
2JH-H = 12.78, Hk(Ax)); 6.69 (2H, 
t, 3JH-H = 7.25, Hf); 7.04 (2H, d, 
3JH-H = 8.50, Hh); 7.29 (2H, s, NH); 7.38 (2H, t, 
3JH-H = 7.62, Hg); 7.57 (2H, d, 
3JH-H = 7.85, He); 8.67 (2H, d, 
4JP-H = 11.19, Hc). 
31P{1H} NMR (161.903 MHz, DMSO–d6): (δ, ppm) -61.47 (2P, s, PTA) ),  1JPt-P 
= 3329.69. 13C{1H} NMR (100.577 MHz, DMSO–d6): (δ, ppm) 45.97 (Ca); 
50.27 (Cj); 72.84 (Ck); 116.09 (Ch); 119.01 (Cd), 121.64 (Cf); 133.15 (Ce); 
134.71 (Cg); 147.46 (Cc); 160.58 (Ci); 172.45 (Cb). FT-IR (KBr): (νmax, cm-1) 
1599 (C=N), 1635 (C=N). Elemental analysis calculated for 
C30H40N12O2S2Pt2P2·5H2O: C, 29.82; H, 4.17; N, 13.93; S, 5.31%. Found: C, 
29.96; H, 3.63; N, 13.93; S, 5.17%. ESI-MS: m/z 1117 (100%, [M]+). M.p.  no 
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3-Methoxy salicylaldimine dithiosemicarbazone (0.081 g, 0.171 mmol), 
triethylamine (0.05 cm3) and cis-[Pt(PTA)2Cl2] (0.196 g, 0.338 mmol) were 
refluxed in ethanol for 5 hours. The precipitate was filtered using a Büchner 
funnel and the product washed with ethanol and diethyl ether. The product 
was obtained as a yellow powder (0.175 g, 95%). 1H NMR (399.952 MHz, 
DMSO–d6): (δ, ppm) 3.52 (4H, s, Ha); 3.84 (6H, s, Hj); 4.31 (12H, s, Hk); 4.50 
(6H, d, 2JH-H = 13.02, Hl(Eq)); 4.57 (6H, d, 
2JH-H = 12.72, Hl(Ax)); 6.62 (2H, t, 
3JH-H 
= 7.83, Hf); 7.02 (2H, d, 
3JH-H = 7.78, Hg); 7.19 (2H, d,
 3JH-H = 8.16, He); 7.29 
(2H, s, NH); 8.65 (2H, d, 4JP-H = 11.18, Hc). 
31P{1H} NMR (161.903 MHz, 
DMSO–d6): (δ, ppm) -60.18 (2P, s, PTA), 1JPt-P = 3321.44. 13C{1H} NMR 
(100.577 MHz, DMSO–d6): (δ, ppm) 45.16 (Ca); 49.40 (Ck); 56.23 (Cj); 72.07 
(Cl); 113.56 (Cf); 114.37 (Cg); 118.047 (Cd); 125.58 (Ce); 146.35 (Cc); 150.93 
(Ch); 151.07 (Ci); 171.63 (Cb). FT-IR (KBr): (νmax, cm-1) 1596 (C=N), 1619  
(C=N). Elemental analysis calculated for C32H44N12O4Pt2P2S2: C, 32.65; H, 
3.77; N, 14.28; S, 5.45%. Found: C, 31.44; H, 3.98; N, 13.13; S, 4.90%. ESI-
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3-tert Butyl salicylaldimine dithiosemicarbazone (0.090 g, 0.170 mmol), 
triethylamine (0.05 cm3) and cis-[Pt(PTA)2Cl2] (0.196 g, 0.338 mmol) were 
stirred  in ethanol for 5 hours. The precipitate was filtered using a Büchner 
funnel and the product washed with ethanol and diethyl ether. The product 
obtained was a yellow amorphous solid (0.166, 86%). FT-IR (KBr):  
(νmax, cm-1) 1594 cm-1 (C=N). Elemental analysis calculated for 
C38H56N12S2P2O2Pt2: C, 37.13; H, 4.59; N, 13.68; S, 5.22%. Found: C, 38.04; 


























































5-Chlorosalicylaldimine dithiosemicarbazone (0.086 g, 0.177 mmol), 
triethylamine (0.05 cm3) and cis-[Pt(PTA)2Cl2] (0.206 g, 0.355 mmol) were 
refluxed in ethanol for 5 hours. The precipitate was filtered using a Büchner 
funnel and the product washed with ethanol and diethyl ether. The product 
obtained was a yellow powder (0.167 g, 79%). 1H NMR (399.952 MHz, 
DMSO–d6): (δ, ppm) 3.55 (4H, s, Ha); 4.31 (12H, s, Hj); 4.50 (6H, d, 2JH-H = 
13.82, Hk(Eq)); 4.58 (6H, d, 
2JH-H = 12.69, Hk(Ax)); 7.07 (2H, d, 
3JH-H = 9.09,  
Hh); 7.26 (2H, s, NH); 7.35 (2H, dd, 
4JH-H = 2.70, 
3JH-H = 8.91, Hg); 7.64 (2H, d, 
4JH-H = 2.84, He); 8.64 (2H, d, 
4JP-H = 10.99, Hc). 
31P{1H} NMR (161.903 MHz,  
DMSO–d6): (δ, ppm) -61.60 (2P, s, PTA), 1JPt-P = 3343.30. FT-IR (KBr):  
(νmax, cm-1) 1595 (C=N), 1631  (C=N). Elemental analysis calculated for 
C30H38N12O2S2Cl2Pt2P2·6H2O: C, 27.85; H, 3.89; N, 12.99; S, 4.95%. Found: 
C, 27.58; H, 3.14; N, 11.58; S, 4.65%. ESI-MS: m/z 1117 (100%, [M-Cl]+); 


























































7.4.3. Synthesis of trithiosemicarbazone complexes 
7.4.3.1. Trithiosemicarbazone Pd(II) complexes 
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Salicylaldimine trithiosemicarbazone (0.044 g, 0.06 mmol), triethylamine  
(0.03 cm3) and cis-[Pd(PTA)2Cl2] (0.0951 g, 0.19 mmol) were refluxed in 
ethanol for 16 hours and stirred for an additional 24 hours at room 
temperature. The precipitate was filtered using a Büchner funnel and the 
product washed with cold ethanol. The product obtained was a yellow powder 
(0.083 g, 87%). 1H NMR (399.953 MHz, DMSO–d6): (δ, ppm) 2.72 (6H, m, 
Ha); 3.33 (6H, m, Hb); 4.28 (18H, s, Hk); 4.41 (9H, d, 
2JH-H = 13.27, Hl(Eq)); 4.55 
(9H, d, 2JH-H = 12.69, Hl(Ax)); 6.55 (3H, t, 
3JH-H = 6.84, Hh); 6.92 (3H, d, 
3JH-H = 
8.27, Hf); 7.04 (3H, s, NH); 7.26 (3H, t, 
3JH-H = 7.94 , Hg); 7.39 (3H, d, 
3JH-H =  
7.91, Hi); 8.31 (3H, d, 
4JP-H = 12.99, Hd). 
31P{1H} NMR (161.903 MHz, DMSO–
d6): (δ, ppm) -40.55 (3P, s, PTA). 13C{1H} NMR (100.577 MHz, DMSO–d6): (δ, 
ppm) 44.48 (Cb); 50.67 (Ck); 54.08 (Ca); 72.66 (Cl); 115.17 (Ch), 118.80 (Ce); 
121.51 (Cf); 133.30 (Cg); 135.05 (Ci); 149.09 (Cd); 162.52 (Cj); 171.15 (Cc). 
FT-IR (KBr): (νmax, cm-1) 1598 (C=N). Elemental analysis calculated for 
C48H66N19S3O3Pd3P3·8H2O: C, 35.81; H, 5.13; N, 16.54; S, 5.97%. Found: C, 
35.58; H, 4.77; N, 16.67; S, 4.70%. ESI-MS: m/z 1466 (25%, [M+H]+). M.p. 





























3-Methoxysalicylaldimine trithiosemicarbazone (0.041 g, 0.05 mmol), 
triethylamine (0.03 cm3) and cis-[Pd(PTA)2Cl2] (0.0782 g, 0.16 mmol) were 
refluxed in methanol for 12 hours and stirred for an additional 24 hours at 
room temperature. The precipitate was filtered using a Büchner funnel and the 
product washed with cold methanol followed by diethyl ether. The product was 
dried in vacuo. The product was obtained as an orange powder (0.046 g, 
57%). 1H NMR (300.077 MHz, DMSO–d6): (δ, ppm) 2.72 (6H, s, Ha); 3.36 (6H, 
s, Hb); 3.78 (9H, s, Hk), 4.31 (18H, s, Hl); 4.44 (9H, d, 
2JH-H = 13.15, Hm(Eq)); 
4.55 (9H, d, 2JH-H = 12.65, Hm(Ax)); 6.46 (3H, m,  Hg); 6.95 (9H, m, Hf, Hh, NH); 
8.33 (3H, d, 4JP-H = 13.18, Hd). 
31P{1H} NMR (121.472 MHz,  
DMSO–d6): (δ, ppm) -36.00 (3P, s, PTA). 13C{1H} NMR (100.577 MHz, 
DMSO–d6): (δ, ppm) 44.91 (Cb); 50.83 (Cl); 53.74 (Ca); 56.98 (Ck); 72.72 (Cm); 
114.18 (Cg), 114.87 (Ch); 118.57 (Ce); 126.85 (Cf); 148.79 (Cd); 151.69 (Ci); 
153.73 (Cj); 170.82 (Cc). FT-IR (KBr): (νmax, cm-1) 1595 (C=N), 1621 (C=N). 
Elemental analysis calculated for C51H72N19S3O6Pd3P3·4H2O: C, 37.63; H, 
4.95; N, 16.35; S, 5.90%. Found: C, 37.31; H, 4.80; N, 16.15; S, 6.53%. ESI-













































































































3-tBu salicylaldimine trithiosemicarbazone (0.082 g, 0.965 mmol) was 
dissolved in MeOH (25 cm3). Triethylamine (0.04 cm3) was added to the 
solution and stirred for 5 minutes. (0.142 g, 0.289 mmol) cis-[Pd(PTA)2Cl2]  
was then added and the solution was stirred for 48 hours at room 
temperature. The yellow precipitate was filtered using a Büchner funnel and 
washed with cold methanol and diethyl ether. The product was dried in vacuo. 
The product was obtained as a yellow powder (0.099 g, 62%). 1H NMR 
(300.066 MHz, DMSO–d6): (δ, ppm) 1.43 (27H, s, Hl); 2.75 (6H, s, Ha); 3.41 
(6H, s, Hb); 4.33-4.54 (36H, m, Hm, Hn); 6.46 (3H, t, 
3JH-H = 7.54,  Hg); 7.21 
(9H, m, NH, Hf, Hh); 8.26 (3H, d, 
4JP-H = 13.44, Hd). 
31P{1H} NMR (121.468 
MHz, DMSO–d6): (δ, ppm) -40.11 (3P, s, PTA). 13C{1H} NMR (100.577 MHz, 
DMSO–d6): (δ, ppm) 29.82 (Cl); 35.66 (Ck); 44.73 (Cb); 51.48 (Cm); 53.85 (Ca);  
72.31 (Cn); 114.39 (Cg), 118.60 (Ce); 130.06 (Cf); 133.76 (Ch); 139.17 (Ci); 
149.95 (Cd); 161.14 (Cj); 169.41 (Cc). FT-IR (KBr): (νmax, cm-1) 1594 (C=N), 
1624 (C=N). ESI-MS: m/z 1634 (30%, [M]+); 818 (70%, [M+2H]2+). M.p. 


























































5-Chlorosalicylaldimine trithiosemicarbazone (0.097 g, 0.124 mmol), sodium 
acetate (0.030 g, 0.362 mmol) and cis-[Pd(PTA)2Cl2] (0.178 g, 0.362 mmol) 
were refluxed in ethanol for 48 hours. The mixture was cooled to room 
temperature and the precipitate filtered, washed with ethanol and diethyl ether 
then dried in vauo. The product obtained was a yellow powder (0.164 g, 84%). 
1H NMR (300.077 MHz, DMSO–d6): (δ, ppm) 2.78 (6H, s, Ha); 3.38 (6H, s, 
Hb); 4.27 (18H, s, Hk); 4.41 (9H, d, 
2JH-H = 12.81, Hl(Eq)); 4.55 (9H, d,  
2JH-H = 12.32, Hl(Ax)); 6.89 (3H, d, 
3JH-H = 8.95, Hi); 7.20 (6H, m, Hh, NH); 7.39 
(3H, d, 4JH-H = 2.74, Hf); 8.19 (3H, d, 
4JH-H = 12.92, Hd). 
31P{1H} NMR (121.472 
MHz, DMSO–d6): (δ, ppm) -36.32 (3P, s, PTA). 13C{1H} NMR (100.577 MHz,  
DMSO–d6): (δ, ppm) 43.93 (Cb); 49.90 (Ck); 52.80 (Ca); 71.82 (Cl); 117.08 (Ci), 
119.02 (Ce); 122.35 (Cg); 131.73 (Cf); 131.99 (Ch); 147.16 (Cd); 160.35 (Cj); 
170.69 (Cc). FT-IR (KBr): (νmax, cm-1) 1597 (C=N). Elemental analysis 
calculated for C48H63N6O3S3Pd3P3Cl3: C, 36.75; H, 4.05; N, 16.97; S, 6.13%. 
Found: C, 35.12; H, 4.03; N, 16.00; S, 5.40%. ESI-MS: m/z 1569 (10%, [M]+); 

















































7.4.3.2. Trithiosemicarbazone Pt(II) complexes 
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Salicylaldimine trithiosemicarbazone (0.074 g, 0.109 mmol), triethylamine 
(0.05 cm3) and cis-[Pt(PTA)2Cl2] (0.185 g, 0.319 mmol) were refluxed in 
methanol for 6 hours and stirred for an additional 12 hours at room 
temperature. The precipitate was collected using a Büchner funnel and the 
product washed with methanol and diethyl ether. The product was obtained as 
a yellow-orange amorphous solid (0.078 g, 41%). 1H NMR (399.953 MHz, 
DMSO–d6): (δ, ppm) 2.70 (6H,  m, Ha); 3.33 (6H, m, Hb); 4.15 (18H, s, Hk); 
4.36 (9H, d, 2JH-H = 13.11, Hl(Eq)); 4.44 (9H, d, 
2JH-H = 12.78, Hl(Ax)); 6.60 (3H, t,  
3JH-H = 7.25, Hh); 6.98 (3H, d, 
3JH-H = 8.49, Hf); 7.10 (3H, s, NH); 7.32 (3H, t, 
3JH-H = 7.22, Hg); 7.46 (3H, d, 
3JH-H =  8.31, Hi); 8.57 (3H, d, 
4JP-H = 11.20, Hd). 
31P{1H} NMR (161.903 MHz, DMSO–d6): (δ, ppm) -61.49 (3P, s, PTA),  
1JPt-P = 3348.80. 
13C{1H} NMR (100.577 MHz, DMSO–d6): (δ, ppm) 44.80 (Cb); 
50.19 (Ck); 53.92 (Ca); 72.79 (Cl); 115.66 (Ch), 118.77 (Ce); 121.29 (Cf); 
132.68 (Cg); 134.29 (Ci); 147.06 (Cd); 160.58 (Cj); 172.32 (Cc). FT-IR (KBr): 
(νmax, cm-1) 1599 (C=N). Elemental analysis calculated for 
C48H66N19S3O3Pt3P3: C, 33.29; H, 3.84; N, 15.37; S, 5.55%. Found: C, 33.07; 


























3-Methoxysalicylaldimine trithiosemicarbazone (0.164 g, 0.213 mmol) in 
methanol (25 cm3) was heated in a round bottom flask. To this, triethylamine 
(0.10 cm3) was added and the solution stirred for 5 minutes. Cis-[Pt(PTA)2Cl2]   
(0.368 g, 0.633 mmol) in hot de-ionised water (25 cm3) was added to the 
solution and the resulting mixture was refluxed for 6 hours and stirred for an 
additional 12 hours at room temperature. Upon cooling a yellow precipitate 
was observed and filtered using a Büchner funnel.The product washed with 
methanol and diethyl ether and dried in vacuo. The product obtained was a 
yellow powder (0.054 g, 14%). 1H NMR (300.066 MHz, DMSO–d6): (δ, ppm) 
2.72 (6H, t, 3JH-H = 6.37, Ha); 3.42 (6H, m, Hb); 3.80 (9H, s, Hk) 4.24 (18H, s, 
Hl); 4.48 (18H, s, Hm); 6.50 (3H, t, 
3JH-H = 7.79,  Hg); 6.86 (3H, s,  
NH); 6.95 (3H, dd, 4JH-H = 1.50, 
3JH-H = 7.65, Hh); 7.07 (3H, dd, 
4JH-H = 1.55, 
3JH-H = 8.24, Hf); 8.51 (3H, d, 
4JP-H = 11.22, Hd). 
31P{1H} NMR (121.468 MHz, 
DMSO–d6): (δ, ppm) -56.90 (3P, s, PTA), 1JPt-P = 3333.81. 13C{1H} NMR 
(75.451 MHz, DMSO–d6): (δ, ppm) 44.09 (Cb); 49.52 (Cl); 53.13 (Ca); 56.23 
(Ck); 72.01 (Cm); 113.67 (Cg), 114.14 (Ch); 118.04 (Ce); 125.55 (Cf); 146.09 
(Cd); 150.98 (Ci); 154.49 (Cj); 171.51 (Cc). FT-IR (KBr): (νmax, cm-1) 1592 
(C=N), 1631 (C=N). Elemental analysis calculated for C51H72N19O6S3Pt3P3: 
C, 33.63; H, 3.98; N, 14.61; S, 5.28%. Found: C, 32.03; H, 4.05; N, 13.79; S, 










































































































3-tBu salicylaldimine trithiosemicarbazone (0.085 g, 0.010 mmol) was 
dissolved in MeOH (25 cm3). Triethylamine (0.04 cm3) was added to the 
solution and stirred for 5 minutes. Cis-[Pt(PTA)2Cl2] (0.167 g, 0.289 mmol) 
was then added and the solution was stirred for 48 hours at room 
temperature. The yellow precipitate was filtered using a Büchner funnel and 
washed with methanol and diethyl ether. The product was dissolved in DCM 
and filtered by gravity. The solvent was evaporated and the product dried in 
vacuo. The product was isolated as a yellow powder (0.069 g, 38%). 1H NMR 
(300.066 MHz, DMSO–d6): (δ, ppm) 1.45 (27H, s, Hl) 2.71 (6H, s, Ha); 3.40 
(6H, s, Hb); 4.27 (18H, s, Hm); 4.44 (18H, m, Hn); 6.53 (3H, t, 
3JH-H = 7.58,  Hg); 
7.07 (3H, s, NH); 7.30 (6H, d, 3JH-H = 7.75, Hf, Hh); 8.58 (3H, d,  
4JP-H = 11.35, Hd). 
31P{1H} NMR (121.468 MHz, DMSO–d6): (δ, ppm) -60.76 
(3P, s, PTA), 1JPt-P = 3340.49. 
13C{1H} NMR (100.577 MHz, DMSO–d6):  
(δ, ppm) 30.02 (Cl); 35.95 (Ck); 44.70 (Cb); 51.27 (Cm); 53.88 (Ca);  72.64 (Cn); 
115.47 (Cg), 119.13 (Ce); 130.09 (Cf); 133.74 (Ch); 139.51 (Ci); 148.21 (Cd); 
159.25 (Cj); 171.31 (Cc). FT-IR (KBr): (νmax, cm-1) 1594 (C=N), 1628 (C=N). 
Elemental analysis calculated for C60H90N19O3S3Pt3P3.4CH2Cl2: C, 34.32; H, 
4.41; N, 11.88; S, 4.29%. Found: C, 34.28; H, 5.23; N, 16.25; S, 4.82%.  
































































               41 
 
5-Chlorosalicylaldimine trithiosemicarbazone (0.158 g, 0.202 mmol) in ethanol 
(25 cm3) was heated in a round bottom flask. To this, triethylamine (0.10 cm3) 
was added and the solution stirred for 5 minutes. Cis-[Pt(PTA)2Cl2]  (0.347 g, 
0.598 mmol) in hot de-ionised water (25 cm3) was added to the solution and 
the resulting mixture was refluxed for 3 hours and stirred for an additional 12 
hours at room temperature. A dark yellow precipitate was obtained and filtered 
using a Büchner funnel. The product washed with ethanol and diethyl ether 
and dried in vacuo. The product obtained was a dark yellow powder (0.196 g, 
54%). 1H NMR (300.066 MHz, DMSO–d6): (δ, ppm) 2.71 (6H, t, 3JH-H = 6.10, 
Ha); 3.39 (6H, m, Hb); 4.23 (18H, s, Hk); 4.43 (9H, d, 
2JH-H = 13.48, Hl(Eq)); 4.51 
(9H, d, 2JH-H = 12.75, Hl(Ax)); 6.99 (3H, d, 
3JH-H = 9.07, Hi); 7.12 (3H, m, NH); 
7.27 (3H, dd, 4JH-H = 2.80, 
3JH-H = 9.02, Hh); 7.52 (3H, d, 
4JH-H = 2.79, Hf); 8.53 
(3H, d, 4JH-H = 11.04, Hd). 
31P{1H} NMR (121.467 MHz, DMSO–d6): (δ, ppm)  
-58.19 (3P, s, PTA), 1JPt-P = 3341.09. 
13C{1H} NMR (75.451 MHz, DMSO–d6): 
(δ, ppm) 43.95 (Cb); 49.27 (Ck); 53.06 (Ca); 71.93 (Cl); 118.07 (Ci), 119.20 
(Ce); 122.50 (Cg); 131.49 (Cf); 131.62 (Ch); 145.28 (Cd); 158.27 (Cj); 172.36 
(Cc). FT-IR (KBr): (νmax, cm-1) 1596 (C=N), 1628 (C=N). Elemental analysis 
calculated for C48H63N19O3S3Pt3P3Cl3: C, 31.42; H, 3.46; N, 14.51; S, 5.24%. 
Found: C, 30.19; H, 3.95; N, 13.65; S, 4.94%.   ESI-MS: m/z 1835 (30%, 














7.5. Synthesis of benzaldehyde thiosemicarbazones 
 









Thiosemicarbazide (0.231 g, 2.530 mmol) was added to MeOH (25 cm3), to 
this benzaldehyde (0.26 cm3) was added and the mixture refluxed for 5 hours 
and stirred for an additional 12 hours at room temperature yielding a clear 
solution. The volume of MeOH was reduced to half of its original volume and 
water was added to precipitate the product. The product was filtered using a 
Büchner funnel, washed with water and dried in vacuo. The product obtained 
was a white powder (0.453 g, 93%). 1H NMR (300.066 MHz, DMSO–d6):  
(δ, ppm) 7.39 (3H, m, He, Hf); 7.76 (2H, m, Hd); 7.87 (1H, s, NH2); 8.05 (2H, br 
s, NH2, Hb); 11.31 (1H, s, NH). 
13C{1H} NMR (100.577 MHz,  
DMSO–d6): (δ, ppm) 127.69 (Ce); 129.06 (Cd); 130.25 (Cf); 134.56 (Cc); 
142.73 (Cb), 178.40 (Ca). FT-IR (KBr): (νmax, cm-1) 1591 (C=N); 871 (C=S). 
Elemental analysis calculated for C8H9N3S: C, 53.60; H, 5.06; N, 23.44; S, 
17.88%. Found: C, 54.76; H, 5.37; N, 24.31; S, 18.10%. 











































Ethane-1,2-dithiosemicarbazide (0.122 g, 0.586 mmol)  was added to MeOH 
(25 cm3). Benzaldehyde (0.12 cm3) was added to this and the suspension 
refluxed for 24 hours and stirred for an additional 16 hours at room 
temperature yielding a white solid. The product was filtered on a Büchner 
funnel, washed with MeOH and diethyl ether and then dried in vacuo. The 
product was obtained as a white powder (0.154 g, 68%). 1H NMR (300.066 
MHz, DMSO–d6): (δ, ppm) 3.87 (4H, s, Ha); 7.37 (6H, m, Hf, Hg); 7.79 (4H, m, 
He); 8.06 (2H, s, Hc); 8.61 (2H, s, -CaNH-); 11.45 (2H, s, -NHN=).  
13C{1H} NMR (100.600 MHz, DMSO–d6): (δ, ppm) 44.00 (Ca); 127.79 (Ce); 
129.07 (Cf); 130.27 (Cg); 134.60 (Cd);  142.86 (Cc), 178.01 (Cb). FT-IR (KBr):  
(νmax, cm-1) 1599 (C=N); 884 (C=S). Elemental analysis calculated for 
C18H20N6S2: C, 56.42; H, 5.24; N, 21.86; S, 16.67%. Found: C, 55.96; H, 5.54; 





















































Benzene-1,4-dithiosemicarbazide (0.140 g, 0.544 mmol)  was added to MeOH 
(25 cm3). Benzaldehyde (0.11 cm3) was added to this and the suspension 
refluxed for 24 hours and stirred for an additional 12 hours at room 
temperature yielding a white solid. The product was filtered using a Büchner 
funnel, washed with MeOH and diethyl ether and then dried in vacuo. The 
product was obtained as a white powder (0.215 g, 91%). 1H NMR (300.066 
MHz, DMSO–d6): (δ, ppm) 7.76 (6H, m, Hg, Hh); 7.92 (4H, s, Ha); 8.24 (4H, m, 
Hf); 8.52 (2H, s, Hd); 10.38 (2H, s, -CbNH-); 12.06 (2H, s, -NHN=).  
13C{1H} NMR (100.577 MHz, DMSO–d6): (δ, ppm) 125.92 (Ca); 128.05 (Cg); 
129.06 (Cf); 130.46 (Ch); 134.43 (Ce); 136.62 (Cb); 143.30 (Cd), 176.43 (Cc). 
FT-IR (KBr): (νmax, cm-1) 1600 (C=N); 860 (C=S). Elemental analysis 
calculated for C22H20N6S2: C, 61.08; H, 4.66; N, 19.43; S, 14.38%. Found:  
C, 60.48; H, 5.07; N, 19.71; S, 14.38%. ESI-MS: m/z 455 (100%, [M+Na]+). 



























































Trithiosemicarbazide (0.211 g, 0.572 mmol) was added to EtOH (25 cm3), to 
this benzaldehyde (0.17 cm3) was added and the mixture refluxed for 12 
hours and stirred for an additional 12 hours at room temperature. Water was 
added to precipitate the cream product, which was then filtered using a Hirsch 
funnel and washed with water. The product was then dried in vacuo. The 
product obtained was a cream powder (0.193 g, 53%). 1H NMR (300.066 
MHz, DMSO–d6): (δ, ppm) 2.70 (6H, m, Ha); 3.45 (6H, m, Hb); 7.38 (9H, m, Hg, 
Hh); 7.73 (6H, s, Hf); 8.04 (3H, s, Hd); 8.37 (3H, m, -CbNH-); 11.38 (3H, s,  
-NHN=). 13C{1H} NMR (100.577 MHz, DMSO–d6): (δ, ppm) 42.16 (Cb); 53.03 
(Ca); 127.59 (Cg); 129.14 (Cf); 130.24 (Ch); 134.62 (Ce); 142.47 (Cd), 177.58 
(Cc). FT-IR (KBr): (νmax, cm-1) 1634 (C=N); 873 (C=S). Elemental analysis 
calculated for C30H36N10S3·4½H2O: C, 50.47; H, 6.35; N, 19.62; S, 13.47%. 
Found: C, 50.07; H, 6.59; N, 23.03; S, 15.47%. ESI-MS: m/z 633 (100%, 












































7.6. Synthesis of arene-ruthenium(II) TSC complexes 
7.6.1. Synthesis of mononuclear ( η6-arene )ruthenium(II) TSC complexes 
 










Benzaldehyde monothiosemicarbazone (0.092 g, 0.513 mmol) in MeOH (25 
cm3) was stirred at ambient temperature. To this,  
[Ru(η6-p-cymene)(µ-Cl)Cl]2 (0.157 g, 0.257 mmol) was added, and the dark 
orange solution stirred for 24 hours at room temperature. After this period, the 
clear orange-red solution is reduced to less than one-quarter of the original 
volume. The solution was added dropwise to diethyl ether (90 cm3) to 
precipitate an orange product. The product was washed with diethyl ether, 
which was removed in vacuo yielding the desired product (0.155 g, 62%). 1H 
NMR (400.200 MHz, CDCl3-d): (δ, ppm) 1.07 (3H, d, 3JH-H = 6.81, Hg); 1.13 
(3H, d, 3JH-H = 6.94, Hh); 2.05 (3H, s, Hp); 2.61 (1H, m, Hi); 4.64 (1H, d,
  
3JH-H = 5.72, Hn); 4.80 (1H, d,
 3JH-H = 5.82, Hk); 4.88 (1H, d, 
3JH-H = 5.79, Ho); 
5.41 (1H, d, 3JH-H = 5.79, Hl); 7.57 (4H, m, He, Hf, -NNH); 8.15 (2H, d,  
3JH-H = 6.99, Hd); 9.05 (1H, s, Hb). 
13C{1H} NMR (100.600 MHz, CDCl3-d): (δ, 
ppm) 18.57 (Cp); 21.39 (Cg); 23.05 (Ch); 30.73 (Ci); 81.35 (Ck); 82.41 (Co); 
87.79 (Cl); 88.78 (Cn); 103.85 (Cm); 127.84 (Cj); 128.86 (Ce); 130.54 (Cd); 
131.78 (Cf); 133.34 (Cc); 161.65 (Cb); 177.54 (Ca). FT-IR (KBr): (νmax, cm-1) 
1618 (C=N); 875 (C=S). Elemental analysis calculated for C18H23N3SRuCl2: 
C, 44.54; H, 4.77; N, 8.66; S, 6.60%. Found: C, 44.22; H, 4.82; N, 7.69; S, 


















































Benzaldehyde monothiosemicarbazone (0.105 g, 0.584 mmol) was dissolved 
in DCM (20 cm3). [Ru(η6-C6H5C3H6COOH)(µ-Cl)Cl]2 (0.196 g, 0.292 mmol) 
was added and the dark orange mixture stirred for 10 hours at room 
temperature. After this period, the solid obtained was filtered, washed with 
diethyl ether and dried under vacuum giving rise to a red powder  
(0.225 g, 75%). 1H NMR (400.200 MHz, CD3OD-d4): (δ, ppm) 1.81 (2H, qn, 
Hn); 2.37 (2H, t, 
3JH-H = 7.14, Ho); 2.44 (2H, t, 
3JH-H = 7.09, Hm); 5.09 (1H, d, 
3JH-H = 5.84, Hh); 5.17 (1H, d, 
3JH-H = 5.89, Hl); 5.29 (1H, t,
 3JH-H = 5.72, Hj); 
5.43 (1H, t, 3JH-H = 5.85, Hi); 5.57 (1H, t, 
3JH-H = 5.77, Hk); 7.71 (3H, m, He, Hf); 
8.24 (2H, d, 3JH-H = 5.86, Hd); 8.81 (1H, s, Hb). 
13C{1H} NMR (100.600 MHz, 
CD3OD-d4): (δ, ppm) 24.36 (Cn); 32.13 (Cm); 32.48 (Co); 81.25 (Ck); 83.14 (Cl); 
86.65 (Cj); 88.36 (Ch); 89.24 (Ci); 106.25 (Cg); 128.63 (Ce); 130.17 (Cd); 
131.77 (Cf); 133.47 (Cc); 162.35 (Cb); 174.98 (Cp); 177.82 (Ca). FT-IR (KBr): 
(νmax, cm-1) 1698 (C=O); 1601 (C=N); 871 (C=S). Elemental analysis 
calculated for C18H21O2N3SRuCl2: C, 41.94; H, 4.11; N, 8.15; S, 6.22%. 
Found: C, 41.25; H, 4.13; N, 6.46; S, 5.51%. ESI-MS: m/z 444 (100%, 














































7.6.2. Synthesis of dinuclear ( η6-arene )ruthenium(II) TSC complexes 
 








































Benzene-1,4-dithiosemicarbazone (0.114 g, 0.263 mmol) was added to MeOH 
(25 cm3). To this, [Ru(η6-p-cymene)(µ-Cl)Cl]2 (0.1618 g, 0.264 mmol) was 
added and the dark orange suspension stirred for 24 hours at room 
temperature. After the 24 hour period a clear red solution is obtained. The 
solvent was evaporated and DCM added to the contents of the flask. Diethyl 
ether (90 cm3) was added to precipitate an orange product. The product was 
washed with diethyl ether which was removed in vacuo yielding an orange 
powder (0.187 g, 68%). 1H NMR (400.200 MHz,  
CDCl3-d): (δ, ppm) 1.09 (6H, d, 3JH-H = 6.74, Hi); 1.15 (6H, d, 3JH-H = 6.82, Hj); 
2.07 (6H, s, Hr); 2.64 (2H, m, Hk); 4.69 (2H, m, Hp); 4.82 (2H, d, 
3JH-H = 5.39, 
Hm); 4.92 (2H, d, 
3JH-H = 4.86, Hq); 5.41 (2H, d, 
3JH-H = 5.67, Hn); 7.58 (12H, m, 
Ha, -NNH, Hg, Hh); 8.19 (4H, d, 
3JH-H = 6.44, Hf); 9.04 (2H, s, Hd); 10.66 (2H, s, 
-CbNH). 
13C{1H} NMR (100.600 MHz, CDCl3-d): (δ, ppm) 18.65 (Cr); 21.40 
(Ci); 23.14 (Cj); 30.76 (Ck); 81.91 (Cm); 82.66 (Cq); 87.93 (Cn); 88.88 (Cp); 
103.97 (Co); 124.35 (Ca); 124.48 (l); 128.90 (Cg); 130.61 (Cf); 131.80 (Ch); 
133.49 (Ce); 135.28 (Cb); 161.45 (Cd); 175.97 (Cc). FT-IR (KBR): (νmax, cm-1) 
1614 (C=N); 869 (C=S). Elemental analysis calculated for 
C42H48N6S2Ru2Cl4·½CH2Cl2: C, 46.94; H, 4.54; N, 7.73; S, 5.90%. Found: C, 
46.43; H, 4.69; N, 7.05; S, 5.78%. ESI-MS: m/z 945 (85%, [M-5H-4Cl+2Na]+). 



























































Benzene-1,4-dithiosemicarbazone (0.082 g, 0.189 mmol) was added to MeOH 
(25 cm3). To this, [Ru(η6-C6H5C3H6COOH)(µ-Cl)Cl]2 (0.122 g, 0.182 mmol) 
was added and the orange suspension stirred for 16 hours at room 
temperature. After this time, a clear deep red solution is observed. The 
solution was filtered by gravity into a round-bottom flask and the solution was 
concentrated to less than one-quarter of the original volume. Excess diethyl 
ether was added to the remaining solution to precipitate the product. The 
orange solid was filtered using a Hirsch funnel, washed with diethyl ether and 
dried in vacuo yielding an orange powder (0.179 g, 89%). 1H NMR (400.200 
MHz, CD3OD-d4): (δ, ppm) 1.81 (4H, qn, Hp); 2.30 (8H, m, Ho, Hq); 4.99 (2H, 
d, 3JH-H = 5.73, Hj); 5.04 (2H, d, 
3JH-H = 6.14, Hn); 5.13 (2H, t,
 3JH-H = 5.63, Hl); 
5.28 (2H, t, 3JH-H = 6.06, Hk); 5.40 (2H, t, 
3JH-H = 5.87, Hm); 7.42 (4H, s, Ha); 
7.57 (6H, m, Hg, Hh); 8.14 (4H, d, 
3JH-H = 5.48, Hf); 8.90 (2H, s, Hd). 
13C{1H} 
NMR (100.600 MHz, CD3OD-d4): (δ, ppm) 25.35 (Cp); 33.19 (Co); 33.60 (Cq); 
82.66 (Cm); 84.69 (Cn); 88.06 (Cl); 89.52 (Cj); 90.19 (Ck); 100.94 (Ci); 125.10 
(Ca); 129.68 (Cg); 131.36 (Cf); 132.59 (Ch); 135.22 (Ce); 137. 00 (Cb); 164.86 
(Cd); 170.61 (Cr); 174.77 (Cc).  FT-IR (KBr): (νmax, cm-1) 1727 (C=O); 1600 
(C=N); 845 (C=S). Elemental analysis calculated for C42H44N6S2O4Cl4Ru2: C, 
45.65; H, 4.01; N, 7.61; S, 5.80%. Found: C, 45.60; H, 4.49; N, 7.03; S, 

















7.7.  X-ray crystallography  
7.7.1.  X-ray data of compound 20 
C18H27N6OSPPd, M = 512.89 gmol
-1, Triclinic, P1, a = 9.4573(4),  
b = 12.3185(5), c = 18.6788(7) Å, α = 92.746(2), β = 104.015(2),  
γ = 94.481(2)º, V = 2099.81(15) Å3, T = 173.2 K, Z = 4. A total of 14900 
reflections were collected giving 7684 unique reflections (Rint = 0.0541) for the 
compound. Data for the structure was collected on a Nonius Kappa-CCD 
diffractometer using graphite monochromated MoKα radiation (λ = 0.71073 
Å). The temperature was controlled by using an Oxford Cryostream cooling 
system (Oxford Cryostat). The strategy for the data collections was evaluated 
using the Bruker Nonius "Collect” program. Data were scaled and reduced 
using DENZO-SMN software.14 An empirical absorption correction was 
applied by using the program SADABS.15 The structure was solved by direct 
methods and refined employing full-matrix least-squares with the program 
SHELXL-97 16 refining on F2. Packing diagrams were produced using the 
program PovRay and graphic interface X-seed.17  
 
7.7.2.  X-ray data of compound 49 
C19H26Cl2N3ORuS, M = 516.46 gmol
-1, Monoclinic, C2/c, a = 16.366(3),  
b = 11.063(2), c = 26.328(5) Å, α = 90.00, β = 104.21(3), γ = 90.00 º,  
V = 4621.0(15) Å3, T = 293(2) K, Z = 8. A total of 12730 reflections were 
collected giving 6097 unique reflections (Rint = 0.1130) for the compound. The 
data were measured using a Stoe Image Plate Diffraction system using 
graphite monochromated MoKα radiation (λ = 0.71073 Å). The structure was 
solved by direct methods using the program SHELXS-97.16 The refinement 
and all further calculations were carried out using SHELXL-97.16  
 
7.8. Biological studies 
7.8.1. In vitro  cytotoxicity studies 
The compounds were evaluated against the oesophageal cancer cell-line, 














squamous cell carcinomas (oesophageal cancer cells of South African 
origin)18 and kindly provided by Professor Rob Veale (University of 
Witwatersrand, South Africa). IC50 determinations were carried out using the 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 
3000 cells were seeded per well in 96-well plates. Cells were incubated at  
37 °C under 5% CO 2 (24 hours), after which aqueous DMSO solutions of each 
compound (10 µl, with a constant final DMSO concentration of 0.2%) were 
plated at various concentrations. After a 48 hour incubation period, MTT (10 
µl) solution was added to each well. After further 4 hour incubation, 
solubilisation solution (100 µl) was added to each well, and plates were 
incubated overnight. Plates were read at 595 nm using a BioTek microplate 
reader. 
 
7.8.2. In vitro  antiparasitic studies   
Cultures of T. vaginalis T1 strain were grown in 5 ml completed TYM 
Diamond’s media in a 37 ºC incubator for 24 hours. 100 mM stocks of the 
compounds were made by dissolving in DMSO and these were screened 
against the T1 strain of T. vaginalis. Untreated and inoculated cells with 5 µl 
DMSO were used as the controls. 5 µl of the 100 mM stock solutions of the 
compounds were further inoculated to a final concentration of 100 µM. Results 
were calculated based on counts utilising a hemocytometer after a 24 hour 
period. For IC50 values, the 100 mM stock solutions were added at 80 µM,  
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